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        Pankita Hemant Pandya 
HIF-1α REGULATES CD55 EXPRESSION IN AIRWAY EPITHELIUM  
Rationale:  CD55 down-regulation on airway epithelium correlates with local 
complement activation observed in hypoxia-associated pulmonary diseases.  
Therefore, we hypothesized that induction of hypoxia inducible factor 1 alpha 
(HIF-1α) in hypoxic airway epithelium, mediates CD55 down-regulation. 
Methods:  Chetomin and HIF-1α siRNA inhibited HIF-1α in hypoxic SAECs (1% 
O2), and mice lungs (10% O2).  DMOG mediated HIF-1α stabilization in normoxic 
SAECs and mice lungs (21% O2).  Transduction of SAECs with AdCA5 also 
stabilized HIF-1α.  CD55 and CA9 transcripts were measured by RT-PCR.  CD55 
and HIF-1α protein expression was assessed by western blots.  In vivo, 
immunohistochemistry (IHC) confirmed CD55 and HIF-1α expression.  C3a and 
C5a levels in bronchoalveolar lavage fluid (BALF) were measured by ELISA. 
Results:  HIF-1α was induced in 6 hour hypoxic SAECs (p<0.05), but CD55 
transcripts were repressed (p<0.05).  CD55 protein was down-regulated by 72 
hours (p<0.05).  CA9 transcripts were elevated by 48 -72 hours (p<0.05 and 
p<0.01, respectively).  In vivo, CD55 transcripts and protein were down- 
regulated by 24 hours post-hypoxia (p<0.01) which corresponded to complement 
activation (p<0.05) in BALF.  However, CA9 was increased (p<0.01).  Chetomin 
(100nM) treatment in 6 hour hypoxic SAECs, recovered CD55 transcripts 
(p<0.01) and protein (p<0.05), but down-regulated CA9 (p<0.05).  Similarly, in 
vivo chetomin (1mg/ml) treatment recovered CD55 protein (p<0.01) and down-
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regulated CA9 (p<0.01).  Silencing HIF-1α (50nM) in hypoxic SAECs restored 
CD55 transcripts by 6 hours (p<0.05), and protein expression by 24 hours 
(p<0.05).  However, CA9 was repressed (p<0.01).  In vivo silencing of HIF-1α 
(50μg) restored CD55 protein expression (p<0.05) but down-regulated CA9 
(p<0.05).  Stabilizing HIF-1α in normoxic SAECs via DMOG (1μM), down-
regulated CD55 transcripts and protein (p<0.01), but increased CA9 within 6-24 
hours (p<0.05 and p<0.01, respectively).  HIF-1α induction by DMOG (1mg/ml) in 
normoxic mice lungs down-regulated CD55 transcripts (p<0.01) and protein 
(p<0.01), but increased CA9 (p<0.05).  Induction of HIF-1α in AdCA5 (50 
PFUs/cell) transduced normoxic SAECs, resulted in CD55 protein down-
regulation (p<0.05), but increased CA9 (p<0.001). 
Conclusions:  HIF-1α down-regulates CD55 on airway epithelium.  Targeting 
this mechanism may be a potential therapeutic intervention for attenuating 
complement activation in hypoxic pulmonary diseases. 
 
 
David S. Wilkes, M.D. Chair 
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I.  INTRODUCTION 
A.  Immune Responses  
The Immune System 
Immune responses can be classified as an intricate network of 
biochemical processes that protect against threats made towards an individual’s 
normal homeostasis.  These threats can be in several forms ranging from foreign 
antigens such as pathogenic microbes (pathogens) to allergenic antigens (1), (2).  
Physical barriers such as epithelial membranes provide the first line of defense 
against such threats (3).  The immune system is comprised of two other defense 
mechanisms commonly referred to as innate and adaptive immunity to provide 
sufficient protection and defense against these attacks (4).   
 
Innate Immune Responses 
 Innate immunity is defined as immediate, non-specific, host defenses 
against foreign antigens (5).  This form of immune response involves several 
fast-acting soluble bioactive molecules such as defensins, chemokines, lipid 
mediators, and complement proteins (2).  Interestingly, complement proteins also 
contribute to innate immunity (2), (6).  Although, immunological memory is not 
associated with innate responses, this form of immune-regulation can still 
discriminate between specific groups of pathogens through toll-like receptors 
(TLRs), cytosolic nucleotide-binding oligomerization domains (NODs), or other 
receptors that recognize pathogen or danger associated molecular patterns 
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(PAMPS or DAMPS) on antigens (3).  Cell-mediated protection in innate 
immunity is also achieved through mechanisms involving phagocytic cells 
(macrophages, monocytes, and neutrophils), natural killer cells (NK cells), and 
cells that release inflammatory mediators (eosinophils, mast cells, and 
basophils).  Phagocytic cells facilitate engulfing of pathogens through 
complement-mediated opsonization, or by binding to the pathogen through their 
scavenger or pattern recognition receptors (PRRs) (3).  The phagocytosed 
pathogen is subsequently enclosed in a phagosome which can fuse with 
lysosomal granules and kill the pathogen by lysosomal enzymes (3).  NK cells 
protect against pathogens by monitoring major histocompatibility complex class I 
(MHC I), which are present on all nucleated cells (3), (4).  If MHC I is present in 
its normal state on the cell surface, then the inhibitory signal is activated on NK 
cells, thereby, preventing cellular destruction (3), (4).  However, if altered or 
abnormal MHC I are recognized by NK cells, then the killing signal is activated, 
and NK cells induce apoptosis (3), (4).  Granulocytes such as eosinophils, mast 
cells, and basophils play a role in innate immunity by releasing inflammatory 
mediators such as leukotrienes that have chemotactic functions to further 
enhance the immune response by recruiting more immune cells to the site of 
inflammation (3).  Mechanisms involved in innate immune responses serve as a 
precursor to initiate activation of more specific form of immunity known as the 
adaptive immune response.    
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Adaptive Immune Responses 
 In contrast to the non-specific and rapid onset of innate immunity, adaptive 
immunity has evolved mechanisms to target pathogens by immune responses 
with specific immunological memory.  This process of targeting pathogens or 
other foreign antigens by specific immune responses, occurs gradually over time 
due to differentiation of naïve lymphocytes to mature effector T cells and anti-
body secreting B cells, as well as, antigen-specific clonal expansion (3).  Both B 
and T cells originate in the bone marrow (3).  However, during the maturation 
process the B cells remain in the bone marrow, while the T cells migrate to the 
thymus (3).  At the termination of the maturation process, these lymphocytes 
migrate to peripheral lymphoid organs where costimulatory signals and MHC 
class II (MHC II) molecules on antigen presenting cells (APCs), such as B cells, 
dendritic cells, or macrophages and present antigen to T cell receptors (TCR) of 
CD4+ T cells for initiation of cell-mediated immunity (3).  A naïve T cell that 
encounters an antigen in a peptide-MHC complex is capable of proliferating and 
differentiating into effector CD4+ T cells that target that specific antigen(3), (7).   
Depending on the transcriptional machinery, the microenvironment, and 
the antigen-specific costimulatory signals involved in CD4+ T cell activation, these 
T cells can differentiate into several T helper cell subtypes (Figure 1) including: T 
helper 1 (Th1), T helper 2 (Th2), T helper 9 (Th9), T helper 17 (Th17), follicular 
helper T cells (Tfh), and regulatory T cells (Tregs) (8).  These T helper cell 
subtypes differ in their ability to produce cytokines and in the type of immune 
response they elicit.  Th1 cells release interferon-gamma (IFN-γ) and interleukin-
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2 (IL-2).  They are known to play a role in autoimmunity, as well as, targeting 
intracellular pathogens (8).  Th2 cells are characterized by release of the 
interleukins IL-4, IL-5, IL-10, IL-13, and IL-31, which help target extracellular 
parasites, and promote allergic diseases such as asthma (8), (9).  Th9 cells are 
characterized by production of interleukin-9 and 10 (IL-9 and IL-10).  This cell 
subset mediates immune responses associated with allergic asthma, intestinal 
inflammation, colitis, and microbial infections (10).   Interleukins 17A, 17F, 21, 
and 22 (IL-17A, IL-17F, IL-21, and IL-22) are released by Th17 cells, which 
contribute to autoimmune diseases, and mount a response against extracellular 
bacteria or fungi (8).  Tfh cells are associated with the release of interleukin 6 (IL-
6) and IL-21, and participate in humoral immunity by activating antigen-specific B 
cells within the follicular areas of the lymphoid tissue (8).  Tregs exist as thymus-
derived (tTreg) and peripherally derived Tregs (pTreg).  In contrast to tTregs 
which readily express transcription factor forkhead box protein 3 (FOXP3) and 
are released from the thymus, pTregs are induced in the periphery to become 
Tregs due to presence of transforming growth factor-beta (TGF-β) (8).  Despite 
the differences in their development, both forms of Tregs produce cytokines IL-
10, TGF-β and interleukin 35 (IL-35) to help attenuate inflammation (11).    
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Figure 1.  Effector T Helper Cell Subsets.  Stimulation of Naïve CD4+T helper 
cells by APCs, results in formation of various effector T helper cells.  Each T cell 
subset can be characterized by the release of specific cytokines.  Adapted from 
O'Shea and Paul; Science, 2010 (12).    
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Similar to the role of MHC II in regulating T cell mediated immunity, MHC 
class I molecules present on all nucleated cells can also activate T cells.  
However they induce activation of CD+8 T cells, commonly known as cytotoxic T 
cells (7).  Cells bearing  “non-self antigens,” are targeted by CD8+ T cells for 
cytotoxic attack via release of granzymes and perforins (3), resulting in 
compromised integrity of cellular membranes.  Cell death induced by CD8+ T 
cells are specific to cells expressing the antigen bound to MHC I.  Thus, sparring 
adjacent cells from programmed cell death (3).   
Adaptive immune responses also involve antibody-mediated protection 
(3), (6).  Naïve B cells are activated in the presence of antigens, and by 
costimulatory signals from T helper cells.  This enables these naïve B cells to 
differentiate into antigen-specific antibody secreting plasma cells (3).  The 
antibody secreting plasma cells are major factors in adaptive humoral immune 
response.  Through somatic hypermutation, affinity maturation, and class 
switching, various antibody isotypes are produced.  There are five 
immunoglobulin (Ig) or antibody isotypes (Table 1 and Figure 2): IgD, IgM, IgG, 
IgE, and IgA.  All naïve B cells have cell surface expression of IgD and IgM (3), 
but IgD is present in very low amounts in the blood (3).  IgM exists in a 
pentameric form, and is the first antibody to be secreted (3).  However, the 
monomeric IgG is the most abundant antibody found in the blood (3).  Low levels 
of IgE, a monomeric antibody, exist in blood and extracellular fluid.  However, 
binding of IgE to its receptors on mast cells induce the release of histamines, 
which modulate allergic reactions or target parasites (3), IgA is found in the 
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dimeric form in bodily secretions such as tears or saliva (3), (13).  Notably, IgG 
and IgA antibodies can be further classified into various subclasses (3), (14).   
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Antibody  Forms Characteristics 
IgD Monomer 
Very low amounts in blood;  Present 
on all naïve B cells; Unknown 
function 
IgM Pentamer/Monomer 
First secreted antibody;  Present on 
all naïve B cells; Activates 
complement 
IgG Monomer Most abundant antibody in blood; Activates complement 
IgE Monomer In blood; Can bind to receptors and release histamines from mast cells 
IgA Dimer/ Monomer In bodily secretions such as saliva or tears; Neutralization activity 
Table 1.  Antibody Isotypes 
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Figure 2.  Antibody Isotype Classification.  Five major antibody isotypes exist.  
These antibodies can be structurally classified as being a monomer, dimer, or 
pentamers.  Retrieved from Medscape (15).    
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Interdependence of Innate and Adaptive Immunity 
 While innate and adaptive immunity are distinguished as two separate 
entities of the immune system (Figure 3), a more precise understanding of these 
responses suggests that the effectiveness of their defense mechanisms depend 
on their co-existence and interaction with one another (5).  Several components 
of the immune system link innate and adaptive immune response to provide a 
more efficient mechanism of protection.  Examples of such components that 
bridge the two immune responses include dendritic cells which serve as APCs in 
adaptive immunity, but also play a role in phagocytosis of pathogens when they 
invade epithelial membranes within innate immunity (16).  Other APCs that bear 
the phagocytic ability, like macrophages, can also link innate and adaptive 
immune responses by releasing cytokines referred to as acute phase proteins 
(3).  These acute phase proteins can also induce innate responses such as 
complement activation (17), but also initiate adaptive immune responses by 
stimulating dendritic cells for migration to lymph nodes where it can interact and 
activate T cells (3).  Recent studies have also shed light on how NK cells, 
previously classified as strict innate immune cells, can also play a role in 
adaptive immune response through properties such as clonal expansion (18).   
Complement proteins also link adaptive and innate immune responses.   
Activation of complement proteins in innate response can also modulate adaptive 
immunity by lowering the threshold for B cell activation, or by binding to their 
respective receptors on T cells or APCs for immune regulation (19).  Several 
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proteins of the complement system that regulate complement activity, have also 
been reported to have an impact on T cell differentiation (20), (21).    
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Figure 3.  Branches Of The Immune System.  The immune system can be 
characterized by innate and adaptive immune responses.  Each one of these 
responses consist of their specific soluble and cellular factors.  Adapted from 
Westover, et al; Autism, 2011 (22).    
 
 
 
 
 
 
 
 
 
Soluble Soluble 
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B.  Complement System 
Complement Proteins 
Known for “complementing the activity of antibodies,” these heat labile 
complement proteins in normal plasma and serum were first discovered in the 
late nineteenth century by Jules Bordet (23), (24).  While the liver serves to be 
the primary site for synthesis of complement proteins (25),  local production of 
complement proteins has also been reported in tissues such as the pulmonary 
epithelium (airway and alveolar type II epithelial cells) (26).  To date, the 
complement system consists of more than 30 soluble or membrane-bound 
proteins (27).  The wide array of proteins comprising the complement system 
range from the C3a and C5a complement receptors (C3aR and C5aR), to soluble 
or membrane-bound regulatory proteins that modulate their activation.  These 
complement receptors and the membrane-bound regulatory proteins are 
expressed on various cell types including phagocytes, epithelial cells, and T cells 
(28), (29), (30).  Other complement proteins are serine proteases that can be 
present as zymogens until they are cleaved into their active forms by enzymatic 
precursors upstream in the signaling cascade  (31), (32).  Their activation can 
initiate further downstream proteolytic cleavage of complement proteins within 
the pathway to elicit an immune responses.  Activation of these complement 
proteins can occur by the serine proteases already present in the complement 
system or by the presence of these proteases in other pathways such as the 
coagulation system (33).  Mechanisms by which these activated complement 
proteins facilitate immune responses against the pathogens involve opsonization, 
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pore formation, or their role as chemoattractants to recruit other immune cells to 
the site of inflammation (34).  Initiation of the complement cascade can occur by 
three different pathways (Figure 4): classical, lectin, and alternative pathways (1).    
 
Complement Pathways 
 Activation of complement by the classical pathway results from the 
formation of immune complexes which involve antigen fixing antibodies such as 
IgM or IgG binding to pathogen surfaces (35).  This interaction allows for the 
complement protein, C1q, to bind to the (Fc) portion of the antibody.  Thus 
allowing the serine proteases, C1r and C1s, to bind to C1q and become 
activated.  Through their autocatalytic activity, complement proteins C1r and C1s 
become activated and mediate the formation of C3 convertase by cleaving 
complement proteins C4 and C2 into C4b and C2a, respectively.  Activated 
complement fragments, C4b and C2a, can associate together on the pathogen 
surface to form the C3 convertase (1), (36), (37), (38).  This C3 convertase can 
subsequently cleave C3 protein into two fragments: the anaphylatoxin C3a 
fragment and C3b, which goes on to form the C5 convertase.  Similar to the 
activity of C3 convertase, C5 convertase mediates the proteolytic cleavage of 
complement protein C5 into C5a and C5b.  C5a is an anaphylatoxin, and C5b 
contributes to formation of the membrane attack complex (MAC) which leads to 
cell lysis (1), (36), (37), (38).    
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The lectin pathway is initiated when mannose binding lectin (MBL) binds 
to carbohydrates present on pathogen surface, necrotic cells, late apoptotic blebs 
(36), (39).  MBL contains a carbohydrate recognition domain (CRD) that allows it 
to function as a soluble receptor binding to mannose rich glycans on pathogens 
(36), (39).  This binding to the pathogenic surfaces, activates mannose 
associated serine proteases (MASPs) resulting in downstream complement 
cascade similar to classical pathway (1), (36).  In the same manner, the lectin 
pathway also results in formation of MAC, and death of the pathogen.    
The alternative pathway varies from the classical and lectin pathways in 
that it activates the complement cascade by a “tickover” process (36), (40).  This 
involves spontaneous hydrolysis of the thioester bond in C3 protein to give it a 
unique conformation compared to C3 observed in the classical and lectin 
pathways (40).  This altered structure of the hydrolyzed C3 can bind to soluble 
Factor B, which results in the proteolytic cleavage of this protein by the serine 
protease, Factor D (36).  Binding of hydrolyzed C3 to the cleaved fragments of 
Factor B can form the C3 convertase of the alternative pathway.  In this manner, 
the alternative pathway acts as an “amplification loop,” because continuous low 
level C3 hydrolysis results in formation of more C3 convertases (36), (41).  The 
alternative pathway is also capable of utilizing C3b from either the lectin or 
classical pathway to activate the “tickover” process (36), (41).  Despite the 
differences in activation and formation of C3 convertases among the three 
complement pathways, they all result in the downstream formation of the MAC 
and in cellular or pathogenic lysis (36).    
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Figure 4.  Complement Pathways.  Complement activation can be initiated by 
three major pathways: classical, lectin, and alternative pathway.  However, all 
three pathways converge to form C3 and C5 convertases, resulting in formation 
of MAC to mediate cell-injury or death.  Adapted from Pandya and Wilkes; 
American Journal of Respiratory Cellular and Molecular Biology, 2014 (36).    
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Role of Complement in Innate and Adaptive Immunity 
Recent advances in recognizing the functional properties of complement 
proteins, highlight their importance in bridging innate and adaptive immune 
responses.  Previously, complement proteins’ role was restricted to innate 
immunity.  However, activated complement proteins with chemoattractant 
properties, such as C3a and C5a, can bind to their respective receptors and 
initiate downstream signaling pathways to regulate T cell differentiation and 
functions of APCs (42).  Heeger’s  group reported that binding of  C5a, to its 
receptor, C5aR, on T cells enhances survival and expansion of these effector T 
cells by inhibiting their apoptosis (43).  Along with the expansion of T cells, 
signaling by complement proteins also affect T cell differentiation.  Blocking the 
signaling by complement receptors, C3aR and C5aR, by gene therapy or 
pharmacological inhibitors on T cells, induces the differentiation of these 
alloreactive effector T cells to be more like pTregs, rather than the Th1 
phenotype (44).  It has also been suggested that C3a and C5a can induce 
distinct signaling pathways that lead to different T cell phenotypes.  This has 
been observed in the murine allergic asthma model where C3a induced the 
formation of Th17 cells through IL-23 production from dendritic cells.  However, 
in these studies C5a signaling inhibited production of Th17 cells (45), suggesting 
differential roles of C3a and C5a.    
While direct binding of C3a and C5a to their receptors on T cells 
influences the subset of T effector cells being produced, C3a and C5a signaling 
on APCs can also contribute to T cell differentiation (42).  It has been reported 
 18 
 
that in certain conditions, C3a and C5a signaling on dendritic cells can induce 
cell surface expression of MHC II, cluster of differentiation 80 and 40 (CD80 and 
CD40, respectively), to initiateTh1 responses (46), (47), (48).  Other APCs such 
as macrophages bearing the C3a and C5a receptors can mediate differentiation 
of T cells into Th1 and Th17 subsets (42), (49).  However, the type of T effector 
cell being produced via complement signaling can greatly vary depending on the 
type of APC involved, the cytokine milieu in the environment, and the disease 
model that is being assessed (42), (49).   
Complement proteins can also modulate B cell functions in adaptive 
immunity.  The threshold for B cell activation can be lowered when the B cell 
receptor (BCR) colligates with a receptor complex consisting of complement 
receptor 2 (CR2) and cell surface proteins known as cluster of differentiation 19 
and 81 (CD19 and CD81, respectively) (50), (Figure 5).  The mechanism by 
which the threshold for B cell activation is decreased involves the antigen binding 
to the BCR, and the opsonized part of the antigen, that consists of C3b, binding 
to CR2  (50).  Complement binding also protects B cells from apoptosis (51).   
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Figure 5.  Complement Augments B Cell Activation.  Co-ligation of co-receptor 
complex and BCR with complement bound antigen lowers the threshold for B cell 
activation.  Adapted from Carroll and Isenman; Immunity Review, 2012 (50).    
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Complement Regulatory Proteins 
 While the complement system plays a pivotal role in immune-mediated 
protection against pathogens or other abnormal cells, excessive complement 
activation can lead to destruction and injury of normal cells or tissues (1), (52).  
Thus, to limit the activation of complement cascade to pathogenic surfaces or 
site of infected or abnormal cells, role of complement regulatory proteins (CRPs) 
becomes critical.  While the well characterized role of CRPs in innate immunity is 
regulation of complement activity (53), they have been recently identified to also 
participate in regulating adaptive immunity (1).  CRPs are present in soluble or 
membrane-bound forms on various cell types (Figure 6), (53), (54) to provide the 
precise balance of sufficient, but not excessive complement activation (1).  In the 
complement pathways, CRPs function by regulating complement activation at the 
level of C3 convertase, C5 convertase, or MAC formation (53).    
 Soluble, or fluid-phase, CRPs that regulate formation of C3 convertases 
include C1 inhibitor (C1INH), C4 binding protein (C4BP), and Factor H (53), (55).  
C1INH regulates complement activity by preventing the autocatalytic activity of 
C1r and C1s, which inhibits their serine protease activity.  In non-inflammatory 
conditions, C1INH, C1r, and C1s are reversibly bound to prevent complement 
cascade (53).  However, when C1q binds to the Fc portion of the antibody in an 
immune complex, C1r and C1s can cleave and inactivate C1INH (Figure 6), (53).  
C1INH, similar to its role on C1q, can also act on mannose-binding protein-
associated serine protease-2 (MASP-2) (27).  C4BP dissociates C3 convertase 
(C4b2a), and acts as a cofactor for Factor I to cleave and inactivate C4b (Figure 
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6), (53), (56).   Factor H regulates C3 convertase in the alternative pathway, and 
is characterized as a functional analogue of C4BP (53).  It functions by 
competing with factor B to bind to C3b, as well as, displacing the already bound 
activated factor B (Bb) to the C3 convertase (Figure 6), (53), (57).  Other soluble 
CRPs such as clusterin and S protein prevent MAC formation by inhibiting 
insertion of terminal complement proteins into the cellular membrane (Figure 6),  
(53).    
 The four membrane-bound CRPs include: complement receptor 1 (CR1), 
cluster of differentiation 46, 55, and 59 (CD46, CD55, and CD59, respectively).  
Similar to fluid-phase CRPs, membrane-bound CRPs also regulate complement 
activation at multiple phases of the pathways.  CR1 expression is restricted to 
hematopoietic-derived cells such as lymphocytes, phagocytes, and erythrocytes 
(53).  It is functionally characterized by dissociating preformed C3 and C5 
convertases, and also mediates cofactor functions for Factor I which cleaves and 
inactivate C3b and C4b (Figure 6), (53).  CD46, also known as membrane 
cofactor protein (MCP) is a type I transmembrane protein that has functions 
similar to CR1 (Figure 6).  However, unlike CR1, expression of CD46 is 
distributed among epithelial cells, endothelial cells, and cells of the hematopoietic 
lineage except for erythrocytes (53).  CD46 expression is restricted to 
reproductive organs in mice (58).  However, the murine homologue of CD46, 
known as complement receptor related protein Y (CRRY) is distributed more 
widely in mice (Figure 6), (59), (60).    
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 Both, CD55 and CD59, are structurally similar in that they are proteins that 
are anchored to the cellular membranes by glycosylphosphatidylinositol (GPI) 
(53).  They are expressed on various types of cells ranging from cells in the 
hematopoietic-lineage, and non-hematopoietic lineage (61), (62), (63).  While 
CD59 acts at the level of MAC to prevent its assembly into the cellular 
membrane, CD55, also known as decay accelerating factor (DAF), functions in a 
similar manner to CR1 and CD46 by dissociating and inhibiting formation of C3 
or C5 convertases (Figure 6), (53), (55).    
 Notably some of these CRPs; such as CD46, CRRY, and CD55; also 
regulate adaptive immunity.  CD46 and CRRY have costimulatory properties on 
human and mouse T cells, respectively (64), (65).  It has been reported the 
complement activation through receptor binding on T cells, enhances 
proliferation and differentiation of effector T cells (44), (66).  However, the 
presence of CD55 on these T cells, aids in regulating the T-cell mediated 
immunity associated with allograft rejection (67).  CD55 is also involved in T cell 
regulation by forming a co-regulatory protein complex with cluster of 
differentiation 97 (CD97) (68).  On monocytes, the short consensus repeat-1 
(SCR-1) of CD55 can interact with epidermal growth factor (EGF) domains 1,2, 
and 5 of CD97 on T cells to enhance T cell proliferation and IFN-γ secretion (68).    
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Figure 6.  Complement Regulatory Proteins.  Activation of complement can be 
regulated by soluble or membrane-bound CRPs.  This regulation can occur in all 
three pathways.  Adapted from Pandya and Wilkes; American Journal of 
Respiratory Cellular and Molecular Biology, 2014 (36).    
 
 
 
 
 
 
 
 
 24 
 
C.  CD55 
 CD55 Structure 
 CD55 (DAF), a GPI-anchored protein, consists of four SCRs that are 
linked together by two cysteine residues (Figure 7), (69).  These SCRs contribute 
to the complement regulating characteristic of CD55 (70).  In particular, SCR 
subunits 2, 3, and 4 are the primary sites at which regulation of complement 
activity from the classical and alternative pathways are mediated (70).  Each one 
of the four SCR subunits are highly enriched with serine and threonine residues 
that serve to properly orient and position the CCPs (Figure 7), (69).  This gives 
rise to variability in molecular weight of the protein (69).  Other post-translational 
modifications such as O-glycosylation of CD55, which serves to stabilize the 
protein structure, also adds another factor of variability to CD55 expression.  At 
the molecular level, alternative splicing results in two different CD55 transcripts 
(mRNA) to produce either the GPI-anchored form or the secreted form of the 
protein (71).  The GPI-anchored form is expressed on membrane of several cell 
types including lymphocytes, erythrocytes, endothelial cells, and epithelial cells 
(Figure 7), (71), and, the soluble form is expressed in bodily fluids such as saliva, 
sweat, tears, plasma, and urine (69), (71).  In the murine model two CD55 (DAF) 
genes, DAF 1 and DAF 2, are differentially expressed.  DAF 1 is GPI-anchored 
protein that is more widely expressed, but DAF 2 is a transmembrane protein that 
is restricted to the testis (72).  Despite the presence of various CD55 isoforms, 
the GPI-anchored CD55 is the predominant form in humans (73), (74).   
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Figure 7.  GPI Structure Of CD55.  CD55 is a membrane-bound GPI anchored 
CRP.  It regulates complement activity at the level of C3 and C5 convertases.  
Adapted from Mikesch et al; Cellular Oncology, 2006 (69).    
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Regulation of CD55 
 CD55 protein is constitutively expressed on cellular membranes (69).  
However, depending on the cell type and the environmental conditions that are 
present, such as the presence of certain cytokines or enzymes, CD55 expression 
can be induced or down-regulated.  Down-regulation of CD55 is observed in 
pathological states involving infection or disease due to the necessity for 
complement activation to destroy the infectious pathogen or diseased 
cells/tissues.  Certain pathogens, such as echovirus, utilize the GPI-anchored 
CD55 as means to enter the host cell (75).  Thereby, down-regulating the surface 
expression of CD55 (75).  Other mechanisms involve down-regulation of CD55 
by mutation in gene that encodes for GPI-anchor, as observed in paroxysmal 
nocturnal hemoglobinuria (PNH) (27).  CD55 expression was also decreased on 
airway epithelium in obliterative bronchiolitis (OB) (76).  However, the process by 
which the down-regulation occurs remains unknown.  Down-regulation of GPI-
anchored CD55 can also be observed when it is cleaved by matrix 
metalloproteinase-7 (MMP-7) (77) or other enzymes such as phosphotidylinostyl 
phospholipase C (PIPLC) (78).  On the contrary, pro-inflammatory mediators 
such as TNF-α, interleukin 1- beta (IL-1β), IFN-γ, and prostaglandin E2 (PGE2) 
can induce the expression of CD55 on cell surface under hypoxic tumorigenic 
conditions (77), (79), (80).  However, a decrease in CD55 expression was 
observed in other forms of tumors such as aggressive breast tumors (81).  This 
variability in CD55 protein expression in tumors or other disease models, can be 
attributed to the origin of tumor, presence of cytokine milieu in the environment, 
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and different cell types associated within the context of that particular disease 
model (81).  Notably, complement activation has been observed in certain 
disease states where down-regulation of CD55 or other CRPs occur.    
 
D.  Complement Activation in Pulmonary Diseases  
Obliterative Bronchiolitis (OB) 
  A form of chronic lung allograft dysfunction (CLAD) is known as OB, is a 
pulmonary disease characterized by irreversible progressive airway obstruction 
mediated by fibrosis (82).  OB is the leading cause of death post lung 
transplantation.  Onset of OB in the clinical setting or in murine orthotopic lung 
transplants show elevated complement activation in their bronchoalveolar lavage 
fluid (BALF) (76).  Interestingly, studies by Suzuki and colleagues have also 
reported down-regulation of CRPs, such as CD55, observed on airway 
epithelium of clinical or murine OB, which may correlate with the local increase of 
complement seen in the BALF (76).  Inhibiting complement activity through C5 
neutralization, restored expression of CRPs such as CD55, and attenuated the 
onset of OB.  Notably, neutralizing IL-17A in the OB murine model also resulted 
in recovery of CD55, along with other membrane-bound CRPs, resulting in down-
regulation of C3a levels in the BALF (36), (76).  Similarly, stimulation of allo or 
autoantigen reactive lymphocytes with C3a, induced IL-17A production, thereby, 
suggesting that the reciprocal regulation between IL-17A and complement 
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proteins contribute to OB pathogenesis by facilitating down-regulation of CD55 
along with other CRPs (36), (76).    
 However, studies by Mohanakumar and colleagues suggest that  
obliterative airway disease (OAD), a model that reproduces some OB features, 
does not require complement activation (83), suggesting that the development of 
airway obliteration in OB may not be dependent on the pivotal role of 
complement proteins (83).  The contrasting reports by Suzuki and Mohanakumar 
regarding the role for complement in OB can be attributed to the difference in the 
animal models being utilized, as well as, pathophysiological differences observed 
between OAD and OB (36), (83), (84).    
 
a) Mice Strain Differences Impact OB Pathogenesis 
 It has been previously reported that lung transplant in mice with complete 
mismatch of major histocompatibility antigens resulted severe rejection and 
necrosis, but onset of OB was not observed (85).  However, histopathological 
features of OB were observed in the murine lung transplant model where the 
C57BL/10 male mice are used as the lung donors and C57BL/6 male mice are 
the recipients in which the lung is transplanted.  While both strains of mice 
possess the H-2b major histocompatibility antigen, they vary in their minor 
histocompatible antigens H-9, Igh-2, and Lv, but the specific roles for these 
particular minor antigens have not been elucidated (85).  Interestingly however, 
naïve C57BL/6 and C57BL/10 mice lungs differentially express proteins involved 
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in the complement cascade.  Figure 8 depicts that C57BL/10 mice express 
higher levels of CD55 in lung homogenates compared to the age and weight 
matched naïve C57BL/6 mice lung homogenates.  On the contrary, CRRY 
expression remains similar between lung homogenates of naïve C57BL/6 and 
C57BL/10 mice (Figure 8).  Similarly, while no difference was observed in C3aR 
expression between lung homogenates of naïve C57BL/6 and C57BL/10 mice 
strains (Figure 9), expression of C5aR was lower in naïve C57BL/10 mice 
compared to the age and weight matched naïve C57BL/6 mice lung 
homogenates (Figure 9).  These results depict strain-specific differential 
expression of proteins in the complement pathways are obtained from male mice.  
Thus, it is also possible that gender of the mice model being utilized is equally as 
important as the strain of the mice.  Notably, factors such as the microbiome and 
environmental factors can also result in different outcomes within the animal 
model for a particular disease.  This is observed in the murine OB model due to 
vendor differences.  As previously mentioned, the onset of OB occurs when 
C57BL/10 male mice donor lungs are transplanted into a C57BL/6 male mice 
(Figure 10) (85).  However, this is only observed if the C57BL/10 male mice 
which are used at lung donors are obtained from Harlan Laboratories but not 
observed when the C57BL/10 mice are obtained from vendors like Jackson 
Laboratory (unpublished data).  Due to higher CD55 expression in naïve 
C57BL/10 mice lungs, their down-regulation post-transplant could prevent the 
regulation of complement which may factor into the post-transplant rejection as 
previously mentioned (Figure 10) (76).  As Wills-Karp and colleagues have 
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reported in the case of experimental allergic asthma C3a and C5a signaling can 
have differential roles and may either be protective or detrimental (45).  Thus, it is 
possible that presence of increased C5aR in naïve C57BL/6 mice may result in 
C5a-mediated protection from lung injury (Figure 10) which may provide an 
explanation as to why C57BL/6 mice lungs are protected from the onset of OB 
when used the donor lungs.  Collectively, these data suggests that factors like 
strain, gender, vendor, and microbiome of the animal model being used to 
recapitulate human diseases such as OB, can influence the outcome.    
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Figure 8.  CD55 Expression Higher In Naïve C57BL/10 Lungs Than In C57BL/6 
Lungs.  (A) CD55 expression was probed in naïve C57BL/6 or C57BL/10 mice 
lungs.  GAPDH was the internal loading control.  (B) Densitometry analysis show 
elevated CD55 in naïve lungs from C57BL/10 vs C57BL/6.  Values represent 
mean+ SEM, n>4, *p<0.05 vs C57BL/6; two-tailed unpaired t-test.  (C) CRRY 
expression was probed in naïve C57BL/6 or C57BL/10 mice lungs.  (D) 
Densitometry analysis show no statistical significance (n. s.) in CRRY expression 
in naïve lungs from C57BL/6 vs C57BL/10.  Values represent mean+ SEM, n>4, 
n. s. two-tailed unpaired t-test.   
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Figure 9.  C5aR Expression Higher In Naïve C57BL/6 Lungs Than In C57BL/10 
Lungs.  (A) C3aR expression was probed in naïve C57BL/6 or C57BL/10 mice 
lungs.  GAPDH was the internal loading control.  (B) Densitometry analysis 
shows no statistical significance (n. s.) in CRRY expression in naïve lungs from 
C57BL/6 vs C57BL/10.Values represent mean+ SEM, n>4, n. s. two-tailed 
unpaired t-test.  (C) CRRY expression was probed in naïve C57BL/6 or 
C57BL/10 mice lungs.  (D) Densitometry analysis show elevated C5aR 
expression in naïve lungs from C57BL/6 vs C57BL/10.  Values represent mean+ 
SEM, n>4, *p<0.05 vs C57BL/10; two-tailed unpaired t-test.   
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Figure 10.  Naïve Lungs From C57BL/10 And C57BL/6 Mice Have Differential 
Complement Protein Expression.  In the murine OB model, naïve C57BL/10 mice 
lungs are donor lungs and are transplanted into naïve C57BL/6 mice.  Naïve 
C57BL/10 mice lungs have elevated CD55 expression compared to C57BL/6 
mice lungs, whereas naïve C57BL/6 mice lungs have higher C5aR expression 
compared to naïve C57BL/10 mice lungs.  This differential expression of 
complement proteins in these naïve mice, may predispose the donor lungs for 
getting OB.    
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Idiopathic Pulmonary Fibrosis (IPF) 
 The heterogeneity of IPF renders it a complex pulmonary disease to 
understand, often with poor prognosis (86), (87).  Pathological manifestations of 
IPF include the presence of fibrotic foci in the lungs through the process known 
as epithelial to mesenchymal transition (EMT), which involves accumulation of 
extracellular matrix proteins such as collagen, as well as, increased activation 
and proliferation of fibroblasts (88).  IPF is the most common and detrimental 
form of idiopathic interstitial pneumonias, due its irreversible nature and unknown 
etiology (88).  While environmental factors such as smoking and genetic 
predisposition have been associated with the onset of IPF, mechanisms 
contributing to IPF remain elusive (89).  However, a role for complement 
activation in IPF patients has been highlighted (36).  Presence of activated 
complement proteins, and immune complexes that activate complement have 
been reported in the BALF of IPF patients (90), (91).  IPF is observed in animal 
models involving bleomycin-induced lung fibrosis (92).  Notably, complement 
depletion in these bleomycin injured animals attenuated lung fibrosis, mediated 
by EMT, which is the hallmark characteristic of IPF (36), (90), (93), (94), 
suggesting a possible correlation between lung fibrosis and complement 
activation (94).  Mechanisms by which complement activation occurs in IPF have 
not been elucidated.  However, indirect evidence for the role of classical pathway 
in complement activation in IPF has been suggested due to the presence of  
immune complexes and autoantibodies targeting the heat shock protein 70 
(HSP-70) in IPF patients (95).  Studies by Vittal’s group indicate down-regulation 
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of CD55 on airway epithelial cells, which may contribute to the EMT process, and 
result in the observed complement activation in IPF or bleomycin-induced lung 
fibrosis (96).    
 
Asthma 
 Asthma is a complex heterogeneous disease that develops due to 
variables such as genetics, and exposure to environmental factors (97), (98).  
The complex nature of this disease can be attributed to its phenotypic and 
pathogenic variability (97).  The disparity in the symptoms associated with this 
multifaceted pulmonary disease, include variation in airway inflammation, mucus 
secretion, and bronchoconstriction (97).    
 At the core of the pathophysiological features of asthma, immune 
mechanisms include production of Th2 cytokines, IL-17A, and IgE  (99), (100).  
Recent studies have indicated a role for complement activation in asthma as 
indicated by elevated C3a and C5a levels in BALF of asthmatic patients 
undergoing allergen challenge (101), (102).  Due to structural and functional 
complexities associated with development of asthma in humans, it is difficult to 
obtain proper animal models for this disease (103).  Among mammalian species, 
asthma is only developed in humans and in certain animals such as cats or 
horses (103).  Therefore, a physiological characteristic of asthma known as 
airway hyperresponsiveness (AHR), which is initiated through acute exposures of 
antigens, such as ovalbumin, is utilized for animal studies involving rodents to 
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model asthma (103).  Studies by Wills-Karp suggest that complement activation 
in asthma does not always correlate with exacerbation of lung injury (45), (104).  
Rather, differential roles of C3a and C5a in ovalbumin-induced allergic AHR can 
result in increase or decrease in AHR severity, respectively (45).  Mechanisms 
that mediate the opposing effects of C3a and C5a in asthma or AHR have not 
been fully elucidated.  However, it has been reported that C3a and C5a play 
reciprocal roles in IL-23 dependent Th17 production (45).  C3a can induce IL-17A 
production from Th17 cells in AHR, as well as, recruit and activate Th2 cells (45), 
(105), (106).  In contrast, the reverse is true for effects of C5a on TH17 cells in 
AHR  (45).  Notably, protective effects of C5a in AHR have also been reported in 
studies by Lewkowich, where it has been indicated that C5a mediated activation 
of plasmacytoid dendritic cells can drive T regulatory induced AHR tolerance 
(107).  This observation of increased complement activation in ovalbumin-
induced AHR model may be correlated to the observed decrease in bronchiolar 
expression of CRPs such as CD55 (J. Lott and D. S. Wilkes, unpublished 
observations).   
 
Lung Ischemia Reperfusion Injury (IRI) 
 Ischemia reperfusion injury (IRI) consists of two critical components: the 
ischemic phase, and the reperfusion phase.  Ischemia is characterized by the 
lack of blood flow to tissue or organ which results in inadequate oxygen levels, 
also known as hypoxia (108).  Reperfusion involves restoring the blood flow to 
the ischemic organ or tissue, restoring oxygenation (108).  Lung IRI occurs 
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during lung transplant (109).  However, IRI can also ensue through assaults 
inflicted on the lung during hypotension, pneumonia, aspiration, and mechanical 
ventilation (110).  One component of the immune response that contributes to 
inflammation in lung IRI within the context of lung transplantation, is activation of 
complement (111).  Studies by Keshavjee and colleagues have utilized methods 
to inhibit activated complement proteins by administering soluble CR1 in a swine 
lung transplant model (112), as well as, in human lung allografts prior to 
reperfusion (113).  These types of methods can improve oxygenation, reduce 
lung edema, and attenuate other inflammation that occur in the transplanted lung 
during IRI (112), (114), (115).   
 One mechanism by which detrimental effects of complement activation in 
lung IRI are achieved, involve the chemoattractant properties of activated 
complement proteins binding to their receptors on leukocytes such as neutrophils 
to initiate further inflammation (109), (116).  Similar to other pulmonary diseases, 
complement activation is not the sole causative factor for pathogenesis of lung 
IRI (116).  While inhibiting complement activation in lung IRI has abrogated some 
lung injury during transplant, the more suitable therapeutic intervention for lung 
IRI may involve targeting factors within lung IRI, such as hypoxia, that induce 
complement activation (108).    
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E.  Lung Hypoxia 
Hypoxia Occurring in Lung Pathologies  
 Hypoxia may be a consequence of lung injury occurring in  IRI,  pulmonary 
hypertension (PH),  IPF, and the acute and chronic injury that may be observed 
in transplanted lungs (117), (118).  The injury can occur in the airways which may 
induce hypoxia (Figure 11).  Prolonged hypoxia is one of many multi-factorial 
injuries inflicted on the donor lung during the transplant procedure, which may 
predispose it for post-transplant rejection.  Initiation of hypoxia occurs in the 
ischemic phase during the lung preservation process, and persists even after the 
lung is reperfused and transplanted (119), (120).  This continuous hypoxic 
condition post-transplant can be attributed to the lack of revascularization of the 
bronchial artery, which provides the main supply of oxygenated blood to the 
lungs (Figure 12), (121), (122).  While the pulmonary arteries and veins are 
reanastomosed during the transplant procedure, the bronchial artery remains 
unvascularized due to difficulties associated with this surgical technique (121), 
(122).  The absence of a systemic arterial blood supply, delivered by the 
bronchial artery under normal conditions, leads to chronic airway hypoxia.  
Studies by Norgaard’s group have assessed the clinical outcomes for restoring 
the bronchial artery during lung transplant (123).  While the revascularization of 
bronchial artery increased survival in transplant patients, the restoration did not 
definitively attenuate rejection.  Therefore, suggesting that other mechanisms 
along with hypoxia may be regulating lung rejection.  It may also be plausible that 
the reanastomosis of bronchial artery does occur either through de novo 
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regrowth by angiogenesis or collateralization, but the microvasculature may still 
be rejected (122), (124), (125).  This could result in hypoxia and activation of the 
immune responses which may affect and injure airway epithelial cells, leading to 
formation of fibrotic lesions which contributes to CLAD (126).  Thus, suggesting 
that in addition to airway hypoxia other factors, such as hypoxia-mediated innate 
and adaptive immune-regulation, may also contribute to post-transplant lung 
rejection or onset of other pulmonary diseases (122), (124).    
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Figure 11.  Structure Of The Airways.  Normal airways allow for sufficient 
oxygenation to an individual.  However, injury to airway epithelium may occlude 
the airways, resulting in inadequate oxygenation and hypoxia.  Adapted from 
American Academy of Allergy, Asthma, and Immunology.    
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Figure 12.  Bronchial Artery.  Bronchial artery are the major source of 
oxygenated blood to the lung (122).  Adapted from Medicine Anatomy Clinically 
oriented from Moore Lecture Notes; Quizlet: Anatomy of the Respiratory Tract, 
Neck, and Thyroid.    
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Effects of Hypoxia on Airway Epithelium 
Injury to airway epithelium during lung transplant or other pulmonary 
conditions, play a key role in intiating pulmonary fibrotic lesions that characterize 
some of these lung diseases, such as IPF and OB (127).  These fibroproliferative 
mechanisms may result from the hypoxic environment of the lung (125).  Several 
studies have indicated a role for hypoxia in induction of fibrogenesis which 
occurs through a process known EMT (128).  This involves transition of adherent 
epithelial cells to motile fibroblasts, resulting in fibrosis (129).  Hypoxic conditions 
mediating EMT, have been vastly studied in cancer metastasis (130).  However, 
recent studies have highlighted the role of hypoxia and hypoxia dependent 
transcription factors, such as hypoxia-inducible-factor-1 alpha (HIF-1α), in 
regulating molecular mechanisms associated with proteins or cell markers of 
mesenchymal or fibroblast cells (131).  Other effects of hypoxia on airway 
epithelial cells involve the induction of apoptosis and inhibition of cellular 
proliferation (132).  Lung hypoxia also generates the production of reactive 
oxygen species (ROS), which results in oxidative damage to airway epithelial 
cells (133).    
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F.  Hypoxia-Inducible Factor-1 alpha (HIF-1α) 
 HIF-1α Structure 
 Being a member of the basic helix-loop-helix-Per-ARNT-Sim (bHLH-PAS) 
protein family (134), HIF-1α structure is comprised of these bHLH and PAS 
motifs to enable interaction and binding to its constitutively expressed co-subunit 
known as hypoxia inducible subunit beta (HIF-1β).  This interaction results in 
formation of heterodimeric complex (134).  Other basic regions present in the 
HIF-1α structure mediate DNA binding (135).  Downstream of bHLH and PAS 
motifs, are regulatory domains that facilitate HIF-1α stability and function in 
hypoxia (135).  Stabilization of HIF-1α is regulated by oxygen-dependent 
degradation domain (ODDD) within the HIF-1α structure.  The ODDD is 
comprised of proline residues critical for oxygen-mediated activity of enzymes 
that enable prolyl hydroxylation (135) which result in HIF-1α degradation.  HIF-1α 
can also be regulated by two transactivation domains located in the carboxy-
terminal end of HIF-1α protein (135).  A slight overlap between ODDD and the 
amino transactivation domain (N-TAD) enables N-TAD to function in regulating 
HIF-1α protein stability by facilitating its binding to E3 ubiquitin ligase (134), 
(135).  This interaction mediates ubiquitination of HIF-1α.  Thus, targeting it for 
proteosomal degradation.  However, the carboxy transactivation domain (C-TAD) 
plays a role in regulating the transcriptional activity of HIF-1α by enabling CH1 
domain of the co-activators to interact with this region of HIF-1α in the 
heterodimeric complex (134).  This interaction between the co-activator and the 
HIF-1α heterodimeric complex promotes the binding of this transcription factor 
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complex to hypoxia responsive elements (HREs) on the promotor regions of HIF-
1α dependent genes (134), (136).  N-TAD is also capable of transactivating HIF-
1α dependent genes.  However, it is done less effectively compared to C-TAD 
which is located in the carboxy termini of HIF-1α structure (136).    
 
Regulation of HIF-1α 
 For physiological adaptations in hypoxic conditions, cells have evolved 
mechanisms to induce expression of genes associated with processes that can 
facilitate and promote survival where inadequate oxygen levels are maintained 
(134), (137).  Up-regulation of such genes under hypoxia are predominantly 
regulated by the transcription factor HIF-1α.  HIF-1α is constitutively transcribed, 
however, post-translational modifications such as hydroxylation, acetylation, and 
ubiquitination regulate its expression (134), (135).  In normoxia where sufficient 
oxygen levels are maintained, prolyl hydroxylases (PHDs) mediate hydroxylation 
of proline residues 402 and 564 (P402 and P564) within the ODDD region of HIF-
1α protein (Figure 13), (134).  Other modifications that occur within the ODDD 
region of HIF-1α include acetylation of lysine residue 532 (K532) by an acetyl 
transferase known as arrest-defective-1 (ARD1) (Figure 13), (134).  Collectively, 
both of these post-translational modifications facilitate the interaction of HIF-1α 
with an E3-ubiquitin ligase known as von-Hippel Lindau protein (pVHL) (Figure 
11).  This E3 ubiquitin ligase functions by ubiquitinating the HIF-1α protein 
(Figure 14).  Thus, promoting the proteosomal degradation of HIF-1α by 26S 
proteosome as previously described (Figures 13, 14), (134).  However, under 
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hypoxic stimuli, lack of sufficient oxygen levels result in inactivation of PHDs, and  
HIF-1α residues P402 and P564 are not hydroxylated (Figures 13, 14).  This 
prevents E3-ubiquitin ligase mediated degradation, and results in stable HIF-1α 
protein expression (134), (135).  Subsequently, HIF-1α translocates to the 
nucleus to form a heterodimeric complex when bound to its constitutively 
expressed subunit HIF-1β, also known as aryl hydrocarbon nuclear translocator, 
(ARNT) (134), (135).  Transcription of HIF-1α dependent genes are mediated by 
binding of the heterodimeric complex interacting with coactivators, such as creb 
binding protein (CBP)/p300 to HREs, on promoter regions of HIF-1α dependent 
genes (134), (136).   
Activity of PHDs in normoxia are dependent on presence of oxygen, and 
iron (138).  They belong to 2-oxoglutartarte (2-OG)-dependent dioxygenase 
family and consists of three isoforms: PHD1, PHD2, and PHD3.  While PHD1 
and PHD3 preferably regulate HIF-2α, PHD2 is the predominant hydroxylase that 
regulates HIF-1α protein stability in normoxia (139), (140).  On the contrary, 
activity of the acetyl transferase, ARD1, is independent of oxygen levels, but the 
protein levels are decreased in hypoxia which may explain why increased 
acetylation of K532 is observed in normoxia compared to hypoxia (134).   
Along with the post-translational modifications of HIF-1α that occur in the 
ODDD region, HIF-1α activity can also be regulated by changes occurring within 
C-TAD (134).  Asparagine residue 803 (N803) is hydroxylated by factor inhibiting 
HIF-1α (FIH-1) which serves to be an oxygen sensor, but does not influence HIF-
1α protein (Figure 13), (134).  FIH-1 regulates the transcriptional activity of HIF-
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1α by inhibiting the C-TAD interaction with the CH1 domain of coactivators 
CBP/p300, and preventing the transcription of HIF-1α dependent genes (134).   
Stabilization of HIF-1α protein can also occur in normoxic conditions.  This 
can be achieved by mammalian target of rapamycin (mTOR), or phosphatidyl-
inositol 3 kinase (PI3K) signaling pathways associated with certain stimuli such 
as growth factors and cytokines (135).  Direct phosphorylation of HIF-1α through 
mitogen-activated protein kinase (MAPK)-dependent pathways can also regulate 
HIF-1α dependent mechanisms by increasing its transcriptional activity (134).   
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Figure 13.  Structure And Regulation Of HIF-1α.  In normoxic conditions, HIF- 1α 
becomes hydroxylated at proline residues 402 and 564 by PHDs.  FIH-1 also 
hydroxylates asparagine 803.  Collectively, all these hydroxylations result in 
degradation of HIF-1α.  In hypoxia, these enzymes responsible for hydroxylation 
are not activated.  Therefore, HIF-1α expression is preserved.  Adapted from 
Yeom et al; Cancers, 2011 (141).    
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Figure 14.  HIF-1α Pathway.  In normoxia, HIF-1α is degraded by 26S 
proteosome due to PHD-mediated hydroxylation.  However, in hypoxic 
environment, expression of HIF-1α is stabilized, because the hydroxylating 
enzymes are inactivated (135).  Adapted from Shimoda and Semenza; American 
Journal of Respiratory Critical Care Medicine, 2011 (142).    
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Carbonic Anhydrase IX, CA9, An Indicator of HIF-1α Transcriptional Activity   
 Hypoxia, through HIF-1α dependent transcriptional mechanisms, is 
responsible for induction of genes critical for cell survival in hypoxic conditions.  
HIF-1α dependent genes play critical role in metabolism, cell survival, cell 
proliferation, angiogenesis, erythropoiesis, and pH regulation during hypoxia 
(143), (144).  Although it has been reported that carbonic anhydrase IX (CA9) 
can be regulated by other transcription factors such as SP1 and SP3 (145), it is 
also known to be the most uniformly induced genes by HIF-1α which makes it a 
robust indicator of HIF-1α dependent transcriptional activity (Figure 15), (146).   
 CA9 is a membrane-bound metalloenzyme that catalyzes reversible 
hydration of carbon dioxide (CO2) to bicarbonate and protons (143), (144), which 
helps regulate pH under hypoxia (Figure 13), (146).  Role of CA9 in regulating pH 
under hypoxia has been studied in tumorigenic conditions (144), where tumors 
adapt to inadequate oxygen levels by reducing their pH (144).  Due to 
bicarbonate being a factor in synthesis of pyrimidine nucleotides, CA9 can also 
mediate cellular growth in hypoxic conditions through bicarbonate formation for 
pH regulation (144), (146).    
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Figure 15.  Carbonic Anhydrase IX (CA9) Is An Indicator Of HIF-1α 
Transcriptional Activity.  It functions in regulating pH in hypoxic environment by 
catalyzing reversible hydration of carbon dioxide (CO2) to bicarbonate and 
protons (144), (146).  It serves to be a good indicator for HIF-1α dependent 
transcriptional activity.  Adapted from Nordfors et al; Oncology, 2013.    
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Stabilizers and Inhibitors of HIF-1α 
 Expression of HIF-1α can be pharmacologically stabilized by hypoxia-
mimetic agents such as cobalt chloride (CoCl2) (147), desferrioxamine (DFO), 
(148), and dimethyloxaloylglycine (DMOG) (149) (Table 2 and Figure 16).  One 
mechanism implemented by hypoxia-mimetics to stabilize HIF-1α expression, is 
to inhibit the activity of PHDs (Figure 16), (150), (151).  Inhibition of PHDs by iron 
chelators, such as CoCl2 and DFO, remove the iron in the active site of PHD 
critical for its function (Figure 16), (152), (153).  As previously mentioned, in 
normoxic conditions PHD1 and PHD3 preferably regulate HIF-2α, whereas, 
PHD2 is known to regulate HIF-1α activity (139).  Since all three isoforms of 
PHDs require iron to function (139), these iron chelators can inhibit the function 
of all three PHDs, thus, resulting in activation of HIF-1α, HIF-2α, and HIF-3α.  
Another hypoxia-mimetic, DMOG, is an analogue of PHD co-substrate known as 
2-oxoglutatarate (154).  DMOG competes with all three PHDs for regulation of 
HIF isoforms (Figure 16).  Collectively, these hypoxia-mimetics result in the 
absence of hydroxylated proline residues in ODDD region of HIF-1α or HIF-2α, 
thus, preventing their ubiquitination-mediated proteosomal degradation.  For 
mechanisms by which HIF-1α specific expression can be induced, techniques 
associated with molecular biology are implemented, such as the use of 
adenoviral vectors encoding HIF-1α gene.  Semenza and colleagues have 
designed a constitutively active HIF-1α, AdCA5, by substituting two critical 
proline residues with threonine and glutamine, as well as, deletion of certain 
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amino acids in the HIF-1α ODDD (155).  These vectors can be utilized to induce 
HIF-1α expression in absence of hypoxia.    
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HIF-1α 
Stabilizers Mechanism of Action Specificity 
CoCl2 Inhibits PHDs by chelation of iron 
Possible targets: HIF-1α 
and HIF-2α  
DFO Inhibits PHDs by chelation of iron 
Possible targets: HIF-1α 
and HIF-2α 
DMOG Inhibits PHDs by competition 
Possible targets: HIF-1α 
and HIF-2α 
AdCA5 Constitutively active HIF-1α vector HIF-1α 
Table 2.  HIF-1α Stabilizers 
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Figure 16.  Pharmacological Stabilizers Of HIF-1α.  In normoxic environment, 
HIF-1α protein can be stabilized by inhibiting the action of PHDs.  This can be 
achieved by DMOG which competes with PHDs or by CoCl2 and DFO that 
chelate irons in the PHD active site (147), (148), (149).  Adapted from Shimoda 
and Semenza; American Journal of Respiratory Critical Care Medicine, 2011 
(142).   
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 Pharmacological inhibitors of HIF-1α include chetomin, or digoxin (Table 
3).  Chetomin is a small molecule, and a natural metabolite of the fungal 
species Chaetomium.  It can inhibit HIF-1α dependent transcriptional activity by 
inhibiting the interaction of C-TAD of HIF-1α or HIF-2α with the CH1 domain of 
coactivators (CBP/p300), (156), (157), (Figure 17).  While chetomin also has the 
capability to inhibit transcriptional activity of HIF-2α, the effects of chetomin on 
HIF-1α are more widely studied.  Digoxin and other cardiac glycosides have been 
reported to inhibit HIF-1α expression independent of the well-known PHD 
mediated ubiquitination-proteosomal degradation pathway (158).  The 
mechanism of action for this may involve digoxin-dependent inhibition of de novo 
HIF-1α synthesis and translation (Table 3), (158).  Due to non-specific effects of 
these pharmacological treatments for HIF-1α inhibition specific mechanisms, 
such as silencing of HIF-1α through small interfering ribonucleic acid (siRNA) or 
short-hairpin ribonucleic acid (shRNA) can also be utilized (Table 3).    
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HIF-1α 
Inhibitors Mechanism of Action Specificity 
Chetomin 
Inhibits HIF-1α 
interaction with 
coactivators 
Targets: HIF-1α, and 
HIF-2α 
Digoxin 
May inhibit de novo 
HIF-1α synthesis and 
translation  
Targets: HIF-1α 
HIF-1α siRNA Transient silencing of HIF-1α gene Targets: HIF-1α 
HIF-1α shRNA 
Short-hairpin mediated 
long-term HIF-1a gene 
silencing  
Targets: HIF-1α 
Table 3.  HIF-1α Inhibitors 
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Figure 17.  Chetomin, A Pharmacological Inhibitor Of HIF-1α.  Chetomin inhibits 
HIF-1α dependent transcriptional activation of genes by disrupting the HIF-1α or 
HIF-2α interaction with the coactivator complex (156), (157).  Adapted from 
Yeom et al; Cancers, 2011 (141).    
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Role of HIF-1α in Airway Epithelium  
 The role for HIF-1α has been described in several pulmonary diseases 
due to presence of hypoxia resulting from obstruction or constriction of airways 
(142), (155).  While vast amount of studies focus on role of HIF-1α on alveolar 
epithelial cells, limited studies in the literature highlight HIF-1α-mediated effects 
on airway epithelium, particularly in airway epithelial cells that are not 
immortalized or transformed.  However, it has been noted that fibrosis 
contributes to obstruction of airways by mediating EMT on airway epithelial cells 
(142).  Studies in other models, suggest that HIF-1α may contribute to the EMT 
process involved in pulmonary fibrosis due to HIF-1α dependent induction of 
EMT regulating transcription factors such as Snail and TWIST (Figure 18), (159), 
(160),  (161).  The EMT regulators can repress epithelial cell markers and induce 
mesenchymal markers of fibroblast-like phenotypes (162).  HIF-1α can also 
protect the airway epithelium from barrier dysfunction associated with oxidative 
damage by induction of antioxidant protein, Sestrin-2, which reduces oxidative 
stress by and preserves tight junction proteins (163).  It has also been reported 
that protection of airway epithelial cells can also be regulated by HIF-1α 
mediated anti-apoptosis (164).    
Notably, HIF-1α has several other roles in the lung which are not restricted 
to the airway epithelium (142).  Due to the hypoxic nature during embryonic 
development, HIF-1α mediates development of the lung by airway branching 
(142), (165).  HIF-1α mediated gene regulation in the lung also involves 
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angiogenesis and metastasis of lung-specific cancers (142), or contraction of 
smooth muscle cells and vascular remodeling as observed in PH.   
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Figure 18.  HIF-1α Mediates EMT On Airway Epithelium.  Hypoxic conditions 
induce airway epithelial expression of HIF-1α and, subsequently, induce the 
expression of transcription factors, such as TWIST, which play a role in EMT 
(159), (160), (161).  Adapted from Aroeira et al; Journal of The American Society 
of Nephrology.  2007 (166).   
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Role of HIF-1α in Innate and Adaptive Immunity 
 Hypoxia initiates injury and inflammatory cascades by production of ROS 
after reoxygenation (167).  However, hypoxic stimuli can also mediate innate and 
adaptive immune responses through mechanisms involving HIF-1α.  Colgan’s 
group reported a role for HIF-1α in regulating innate immunity by showing that 
HIF-1α dependent induction of epithelial CRP, CD55, can remove neutrophils 
following their transmigration (80).  Notably, HIF-1α also regulates transcription 
factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB), that play a part in innate immunity (168).  PHDs, enzymes that regulate 
HIF-1α degradation, also regulate NFκB activity by inhibiting IκB kinase-beta 
(IKKβ).  This IKKβ enzyme is responsible for phosphorylating and degrading I 
kappa B alpha (IκBα), resulting in NFκB release and activation (169).  Thus, 
when PHDs are not active in hypoxia due to insufficient oxygen levels, HIF-1α 
and NFκB become activated (169).    
HIF-1α has also been linked to adaptive immunity because of its role in 
regulating Th17 and Tregs (170), (171).  A transcriptional complex forms when 
HIF-1α binds to RAR-related orphan receptor gamma t (RORγt), and coactivator, 
p300.  This complex can then bind to the IL-17 promoter region and initiate 
transcription this and other Th17-specific genes (171).  Transcriptional activation 
of RORγt by HIF-1α can also regulate generation of Th17 cells (171).  In 
contrast, HIF-1α negatively regulates Treg cells by binding to FOXP3, 
transcription factor involved in Treg development, and targeting it for degradation 
(171).  It has also been reported that HIF-1α also mediates activation and 
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maturation of dendritic cells which enables them to activate allogeneic T cells 
(172).  These studies suggest that the presence of lung hypoxia not only affects 
airway epithelium, but may also affect lymphocytes or other leukocytes via 
induction of HIF-1 α.   
 
Other HIF Isoforms 
 Contrary to the ubiquitous and well-studied hypoxia regulated transcription 
factor HIF-1α, the role of other members of the bHLH-PAS family, such as 
hypoxia inducible transcription factors hypoxia-inducible factor 2 alpha (HIF-2α) 
and hypoxia-inducible factor 3 alpha (HIF-3α), have not previously been well-
recognized (135).  However, recent studies highlight some of their functional 
characteristics.  While all isoforms of HIF proteins share structural and functional 
similarities, their expression varies in organ or cell-specific manner (173).  
Expression of HIF-1α is ubiquitous, however, it has been reported to be 
predominantly expressed in epithelial cells (135).  Whereas, expression of HIF-
2α and HIF-3α are more cell specific, and restricted lung endothelium, heart, or 
the brain (134), (140).  Notably, it has also been reported that HIF-2α and HIF-3α 
can also be induced in epithelial cells of the lung (174), (175).   
 Cooperative interaction between HIF-1α and HIF-2α in hypoxia has been 
observed.  While HIF-2α can mediate some HIF-1α dependent functions in 
hypoxia, such as erythropoiesis (176), non-redundant functions between the two 
isoforms have also been noted.  These distinct differences can be attributed to 
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factors such as the variability in amount of time required for hypoxic exposure, 
the cell type involved, or temporal differences associated with induction of HIF-1α 
and HIF-2α (135).  It is also possible that due to the short half-life of HIF-1α, 
expression of HIF-2α may be induced following HIF-1α protein degradation (135), 
(177).  In contrast, while HIF-3α can mediate gene transcription by binding to 
HREs on promoter regions, a splice variant of HIF-3α known as inhibitory PAS 
(IPAS) can serve to be a negative regulator of HIF-1α (134).  This negative 
regulation of HIF-1α by HIF-3α is mediated through the interaction of IPAS to the 
N-TAD of HIF-1α (134).   
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G.  Research Goal 
 Prolonged hypoxia occurs in the airways post-lung transplant, and in 
pulmonary diseases associated with obstruction of the airways by fibrosis or 
bronchiolar constriction (122), (178).  Interestingly, these particular pulmonary 
diseases, such as IPF and OB, have also shown local complement activation 
which correlates with the observed airway epithelial down-regulation of 
membrane-bound CRPs such as CD55 (Figure 19), (76), (96).  Wilkes and 
colleagues have reported down-regulation of CD55 transcripts occurring as early 
as 24 hours post-transplant prior to initiation of any alloimmune responses (76).  
Down-regulation of CD55 on airway epithelium of lung isografts (data not shown), 
further confirmed that its suppression was independent of an alloimmune 
response.  These data suggest that injury to the donor lung during the transplant 
procedure, like hypoxia from IRI, may regulate CD55 expression.  Studies by 
Vittal’s group have also reported down-regulation of airway epithelial CD55 
expression, and local complement activation in IPF patients (96).  Due to this 
rapid CD55 down-regulation observed in pulmonary diseases associated with 
epithelial injury and hypoxia, we sought to determine if hypoxia regulated airway 
epithelial CD55 expression.  Specifically, our goal was to assess if HIF-1α 
regulated CD55 expression on airway epithelium.    
 
H.  Hypothesis 
 HIF-1α regulates CD55 expression on airway epithelium.     
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Figure 19.  Down-regulation Of CD55 On Airway Epithelial Cells.  CD55 
expression is present on normal airway epithelium which protects against 
complement-mediated lung injury.  Hypoxia induced HIF-1α mediates the loss of 
CD55 expression on airway epithelium.  Thus, resulting in complement related 
lung injury and induction of the fibrotic cascade.  Adapted from Mouse Lung 
Anatomy; Revival Corp.    
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II.  MATERIALS AND METHODS 
A.  Human Small Airway Epithelial Cells (SAECs) 
Normal primary human SAECs, from different donors, were purchased 
from (Lonza Clonetics, Walkersville, MD, USA), and cultured in sterile conditions 
(96).    
 
B.  Animals (Mice) 
C57BL/10 or C57BL/6 male mice 6-8 weeks old (25–30g) were purchased 
from (Harlan, Indianapolis, IN, USA).  Animals were maintained in pathogen-free 
environment, and housed in the Laboratory Animal Resource Center at Indiana 
University School of Medicine, according to institutional guidelines.  All studies 
were approved by the Indiana University School of Medicine Institutional Care 
and Use Committee (76).  For all in vivo hypoxia studies C57BL/10 male mice 
were utilized.   
 
C.  Formulations of Buffers and Media 
SAECs Growth Medium (SAGM) 
To prepare a 100 ml of SAGM, 100 ml of small airway basal medium 
(SABM) (Lonza Clonetics, Walkersville, MD, USA) was added into a 1 L sterile 
beaker.  To this, the following components (Lonza Clonetics, Walkersville, MD, 
USA) were added: 100 μl of epinephrine, 100 μl transferrin, 100 μl retinoic acid, 
100 μl insulin, 100 μl gentamicin, 100 μl human epidermal growth factor (hEGF), 
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100 μl hydrocortisone, 100 μl triiodothyronine, 400 μl bovine pituitary extract 
(BPE), and 1 ml bovine serum albumin (BSA).  The media was mixed by 
pipetting the basal medium containing the growth supplements, and stored at 
4oC until ready for use.    
 
Washing Buffer (Western Blot) 
In a 1 L bottle, 100 ml sterile 10X phosphate buffered saline (PBS) was added 
to 900 ml Milli-Q H2O.  To give the wash buffer its detergent-like characteristics, 
500 μl of Tween-20 (Sigma Aldrich, St. Louis, MO, USA) was also added to the 
mixture.   
 
RNA Lysis Buffer 
In a 15 ml canonical tube, 10 μl of beta-mercaptoethanol (β-ME) (Sigma 
Aldrich, St. Louis, MO, USA) was added to 990 μl of RLT lysis buffer (Qiagen 
Inc., Valencia, CA, USA) to obtain 1:100 dilution.    
 
D.  Culturing of SAECs 
 Cryopreserved normal human SAECs obtained from (Lonza Clonetics, 
Walkersville, MD, USA), were thawed in 37oC water bath, and collected into a 50 
ml tube.  Cells were washed with 1 ml SAGM, and spun down at 1500 
revolutions per minutes (rpm) for 5 minutes.  Supernatant was aspirated off, and 
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cell pellet was resuspended in 10 ml SAGM for culturing in one T75 tissue culture 
flask.  This was termed passage 0.  Once SAECs reached 70-80% confluency, 
the cells were sub-cultured and passaged further.  SAECs were rinsed with 
HEPES-buffer saline solution (Lonza Clonetics, Walkersville, MD, USA), and 6 ml 
of trypsin (Lonza Clonetics, Walkersville, MD, USA), was added to the cells for 2-
4 minutes to disrupt the adherent cell monolayers.  Following the disruption of 
cell adherence, 12 ml of trypsin-neutralizing solution (Lonza Clonetics, 
Walkersville, MD, USA), was added to inhibit the activity of trypsin.  SAECs were 
collected and spun down at 1500 rpm for 5 min.  Supernatant was aspirated off, 
and cell pellet was resuspended in 20 ml of SAGM to culture into two T75 tissue-
culture flasks (10 ml cell suspension/ flask).  This served to be passage 1.  
Similarly, cells were sub-cultured again to passage 2.  However, four T75 tissue-
culture flasks were used with 10 ml cell suspension/flask).  At this point, SAECs 
were either sub-cultured to passage 3 for experiments or harvested for 
cryopreservation until further use.   
 For cryopreservation of SAECs, cells were collected by tryspin/EDTA and 
trypsin-neutralizing solution, as indicated above.  Cells were spun down for 5 
minutes at 1500 rpm and media was aspirated off.  The remaining cell pellet was 
resuspended in 1ml total volume containing 80% SAGM, 10% dimethyl sulfoxide 
(DMSO) (Sigma Aldrich, St. Louis, MO, USA), and 10% fetal bovine serum (FBS) 
(Thermo Fisher Scientific, Rockford, IL, USA).  This 1 ml containing SAECs was 
transferred into a cryovial and a slow freeze process of cells was implemented by 
placing them in Mr. FrostyTM freezing container (Thermo Fisher Scientific, 
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Rockford, IL, USA) for 12 hours.  For long-term storage of SAECs, the cryovials 
containing the cells were placed in liquid nitrogen until ready for use.  All SAEC 
studies were performed at cell passage 3.   
 
E.  Preparation of RNA Lysates 
Preparation of Cellular RNA 
 To obtain RNA lysates for studies involving SAECs, 150 μl of the prepared 
RLT lysis buffer (Qiagen, Valencia, CA, USA) (as indicated above) was added to 
the cells in tissue culture plates.  The cells were then scraped off, collected, and 
transferred to an RNAse-free tube (Qiagen, Valencia, CA, USA).  RNA from 
these cellular lysates were extracted using the mini RNeasy RNA extraction kit 
(Qiagen, Valencia, CA, USA) according to manufacturer’s instructions.    
 
Preparation of RNA from Mice Lungs  
  To extract RNA from mice lungs, a hand held homogenizer was used to 
ensure that the lungs with 700 μl of Tri-reagent (Molecular Research Center 
Incorporation) were properly homogenized.  Following this, the lung 
homogenates were mixed with 7 μl of polyacryl carrier (Molecular Research 
Center, Inc., Cincinnati, OH, USA).  For phase separation, 100 μl of 1–bromo–3–
chloropropane (BCP) (Molecular Research Center Incorporation) was added to 
the lung homogenate following the addition of polyacryl carrier.  This lung 
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homogenate mixture was spun down at 14000 rpm for 15min.  The clear 
supernatant was then transferred to the RNAse free columns (Qiagen, Valencia, 
CA, USA).  RNA was collected, and extracted using the RNeasy RNA extraction 
kit (Qiagen, Valencia, CA, USA) as suggested by manufacturer’s instructions.    
 
F.  Preparation of Protein Lysates 
Preparation of Protein Lysates from Cells and Mice Lungs  
Cytoplasmic/nuclear extraction kit (Thermo Fisher Scientific, Rockford, IL, 
USA) was used to collect cytoplasmic and nuclear fractions from SAECs or mice 
lung homogenates.  This was used to detect CD55 and HIF-1α, respectively, as 
indicated in the protocol provided by the manufacturer.  Nanospectrophotometer 
(Nanodrop 1000; Fisher Scientific, Wilmington, DE, USA) was used to measure 
protein concentration.  For detection of cytoplasmic proteins in SAECs and in 
mouse lung homogenates, primary antibodies specific to CD55 (Santa Cruz 
Biotechnology sc-9156 (H-319) Santa Cruz, CA, USA), beta-actin (β-actin) 
(Abcam ab8224, Cambridge, MA, USA), CD46 (Santa Cruz Biotechnology 
(M177) sc-52647), CRRY (Santa Cruz Biotechnology (M180) sc-30214), GAPDH 
(Meridian Life Sciences H86504M), C3aR (NBP2-15649, Novus Biologicals, 
Littleton, CO, USA), C5aR (NBP1-61567, Novus Biologicals, Littleton, CO, USA), 
and vinculin (Abcam ab18058, Cambridge, MA, USA) were used as indicated by 
their respective manufacturer’s instructions.  Membrane cytoskeletal proteins 
vinculin and β-actin were used as the loading controls depending on their 
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availability at the time of the protein assessment.  Nuclear proteins were detected 
in SAECs or mouse lung homogenates by incubation with antibodies specific to 
HIF-1α (R&D Systems AF1935, Minneapolis, ME, USA), and the nuclear loading 
control lamin β1 (Abcam ab16048, Cambridge, MA, USA) according to the 
manufacturer’s protocol.  Following the incubation with their specific primary 
antibodies, polyvinylidene fluoride (PVDF) membranes were washed three times 
with tris-buffered saline with Tween-20 (TBS-T).  Subsequently, the blots were 
then incubated with their corresponding horseradish peroxidase (HRP) -
secondary antibody: goat, rabbit, or mouse (Jackson ImmunoResearch, West 
Grove, PA, USA).  Supersignal West Pico or Femto (Thermo Fisher Scientific, 
Rockford, IL, USA) were used for detection of protein by chemiluminescence.  
Quantification of proteins were performed by densitometric analyses as 
previously described (96).    
 
G.  Intratracheal Instillation  
 C57BL/10 male mice (Harlan, Indianapolis, IN, USA) were anesthesized 
with isoflurane until no signs of reflex were observed.  Due to midline region of 
the neck being the site for the procedure, mice fur was shaved from this region, 
and Betadine (Purdue Products, Stamford, CT, USA) solution was applied to the 
area.  In the neck region of these mice, skin incision of approximately 1 cm was 
made to separate the muscles and expose the trachea for instillation.  To instill 
50 μl of instillate directly into the trachea, a 30 gauge needle (BD precision glide 
needles, Franklin Lakes, NJ, USA), that is bent at a 90 degree angle, was used.   
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Vet bond skin glue (3M Animal Care Products, St.  Paul, MN, USA) was used to 
patch up the incision.  Following the instillation and sealing of the injured site, 
mice were monitored for normal breathing, and full recovery following the 
procedure (179).    
 
H.  Exposure to Hypoxia 
In Vitro Studies (SAECs) 
 To recapitulate hypoxic conditions in vitro, SAECs were placed in hypoxic 
chamber (The Baker Company, Ruskinn Technology Ltd., Sanford, ME, USA), 
and exposed to 1% O2 for various time-points.  SAECs exposed to ambient 
normoxic O2 concentration of 21%, served as our controls (180), (181).    
 
In Vivo Studies (Mice) 
 For hypoxic animal studies, C57BL/10 male mice (Harlan, Indianapolis, IN, 
USA), were placed in a custom-made hypobaric hypoxia chamber, and exposed 
to 10% O2 for 24 hours.  The chamber mediates slow, gradient decrease in 
oxygen levels from the normal (control) 21% O2 to the hypoxic 10% O2.  The 
normoxic control group consisted of age-matched C57BL/10 male mice exposed 
to the ambient 21% O2 that is present in the atmospheric air.  Animals were 
allowed ad libitum access to food and water (180).    
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I.  Preparation of Chetomin 
Stimulation of SAECs with Chetomin 
 For pharmacological inhibition of HIF-1α in cells, SAECs were treated with 
100nM of chetomin (Sigma-Aldrich, St. Louis, MO, USA) 2 hours prior to the 
hypoxic exposure.  The stock 1mg of chetomin was reconstituted in 1.2 ml 
DMSO to obtain 0.8 mg/ml chetomin.  To prepare 100nM of chetomin, 1.3 μl of 
the 0.8 mg/ml chetomin was diluted in 14.998 ml SAGM.  The 100nM chetomin 
was mixed by vortexing, and 300 μl/well were added to the cells.  DMSO was 
used as the appropriate vehicle controls.  For RNA analysis, SAECs were treated 
with 100 nM of chetomin for 2 hours in normoxic conditions, followed by 6 hours 
of hypoxic (1% O2) exposure.  To obtain protein data, SAECs were treated with 
100 nM chetomin for 2 hours in normoxic conditions, followed by 24 hours of 
hypoxic exposure (1% O2).  This longer hypoxic exposure for protein data was 
performed due to lag phase between transcript and protein expression.   
 
Intratracheal Instillation of Chetomin in Mice 
 For in vivo pharmacological inhibition of HIF-1α, 1 mg/ml of chetomin was 
intratracheally instilled in C57BL/10 male mice (Harlan, Indianapolis, IN, USA) 
prior to 24 hour hypoxic (10% O2) exposure.  For chetomin preparation, the stock 
1 mg chetomin was reconstituted in 100 μl DMSO to give 10mg/ml.  To obtain 1 
mg/ml chetomin in total volume of 50 μl for intratracheal instillation in mice, 5 μl 
of the 10 mg/ml chetomin was diluted in 45 μl of 1X PBS.  Intratracheal instillation 
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was performed as stated above (179).  Due to the slow gradient decrease in 
oxygen levels mediated by the animal hypoxic chamber, assessment of RNA and 
protein analysis in hypoxic animals could not be performed prior to 24 hours of 
hypoxia.  Thus, all in vivo chetomin RNA and protein analysis were performed at 
24 hours of hypoxia following intratracheal instillation of 1 mg/ml chetomin.    
 
J.  HIF-1α siRNA Preparation 
Transfection of SAECs with HIF-1α siRNA or Control siRNA 
 In vitro silencing of HIF-1α in hypoxic SAECs was achieved by 
lipofectamine- mediated transfection with HIF-1α small interference RNA (siRNA) 
sequences that target human HIF-1α (M-004018-05-0005; Dharmacon 
Technologies, Lafayette, CO, USA).  The transfection process involved 
formulating siRNA-lipofectamine complexes to mediate delivery into the cells.  
The formation of these complexes were achieved by diluting 50 nM of HIF-1α 
siRNA or the control siRNA known as RNA Induced Silencing Complex (RISC) 
siRNA (D-001600-01-05; Dharmacon Technologies, Lafayette, CO, USA) with 
Opti-MEM I reduced serum medium (Gibco, Life Technologies, Grand Island, NY, 
USA), and dilution of 5 μl lipofectamine (Invitrogen, Life Technologies, Grand 
Island, NY, USA) with Opti-MEM as indicated by the manufacturer’s protocol.  
Transfection of these SAECs with HIF-1α siRNA or the control siRNA was 
mediated by the direct addition of these complexes to the cells for 6 hours.  
Subsequently, the transfection medium was replaced with growth medium, and 
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the transfected cells were cultured in hypoxic conditions for additional 6 hours or 
24 hours for CD55 RNA and protein analysis, respectively.    
 
Intratracheal Instillation of HIF-1α siRNA or Control siRNA in Mice 
For in vivo knock-down of HIF-1α, HIF-1α siRNA was administered into 
mice lungs via intratracheal instillation.  To complex the siRNA and lipofectamine 
together for delivery into the mice lungs, 50 μg HIF-1α siRNA targeting mouse 
HIF-1α (L-040638-00-0005; Dharmacon Technologies, Lafayette, CO, USA), or 
50μg control RISC siRNA (D-001600-01-05; Dharmacon Technologies, 
Lafayette, CO, USA), as well as, 5 μl lipofectamine (Invitrogen, Life 
Technologies, Grand Island, NY, USA) were diluted in Opti-MEM I reduced 
serum medium (Gibco, Life technologies, Grand Island, NY, USA) as indicated 
by the manufacturer’s instructions.  Intratracheal instillation of HIF-1α or control 
siRNA in mice lungs occurred after the siRNA- lipofectamine were complexed 
together at room temperature for 20 minutes (179).  Following the 72 hours post-
intratracheal instillation of HIF-1α or control siRNA, the mice were placed in the 
hypoxia chamber for 24 hours.    
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K.  Preparation of DMOG 
Stimulation of SAECs with DMOG 
 For pharmacological stabilization of HIF-1α in cells, SAECs were treated 
with 1 μM of DMOG (Sigma-Aldrich, St. Louis, MO, USA).  DMOG was prepared 
by reconstituting the 10 mg stock with 200μl of 1X PBS to obtain 50 mg/ml 
DMOG.  To dilute down to 1 μM, 3.5 μl of the 50mg/ml DMOG was diluted in 
996.5 μl of 1X PBS to get 1000 μM of DMOG.  This was followed by diluting 10 μl 
of 1000μM DMOG with 9990 μl of SAGM to get 10 ml of 1 μM DMOG.  The 1 μM 
DMOG was mixed by vortexing, and 300 μl/well were added to the cells.  1X PBS 
was used as the appropriate vehicle control.  For RNA analysis, SAECs were 
treated with 1 μM of DMOG 6 hours in normoxic conditions (21% O2).  For 
protein analysis, SAECs were stimulated with 1 μM of DMOG for 24 hours in 
normoxic conditions (21% O2).   
 
Intratracheal Instillation of DMOG in Mice  
 In vivo, HIF-1α expression was stabilized in normoxic conditions by 
intratracheal instillation of C57BL/10 male mice (Harlan, Indianapolis, IN, USA) 1 
mg/ml DMOG.  To prepare 1 mg/ml DMOG, 10 mg stock of DMOG was 
resuspended in 200 μl of 1X PBS to get 50 mg/ml DMOG.  DMOG was then 
diluted by taking 1 μl of 50 mg/ml DMOG, and adding it to 49 μl of 1X PBS to 
obtain 50 μl of 1 mg/ml DMOG.  Intratracheal instillation of the 1 mg/ml DMOG in 
50 μl was performed as stated above (179).  Due to the specific nature of DMOG 
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activity on HIF-1α stabilization, RNA and protein analysis of these mice were 
done as early as 6 hours post-DMOG instillation.   
 
L.  Stimulation of SAECs with AdCA5 
 Constitutive HIF-1α expression in normoxic SAECs was mediated by gene 
therapy involving adenoviral vector, AdCA5.  Modifications within the ODDD 
region of HIF-1α, such as amino acid deletions (residues 392-520) and two point  
mutations ( Pro567Thr and Pro658Gln) (182), led to stabilization and activation of 
HIF-1α even in the absence of hypoxia (Vincent and Kelly).  AdCA5 and the 
control vector for transduction efficiency, AdLacZ, (encoding Beta-galactosidase), 
were generously given to us by Dr. Gregg Semenza from John Hopkins 
University.  SAECs were transduced for 24 hours with 50 plaque forming units 
(PFUs)/cell of AdCA5 or AdLacZ under normoxic conditions (182).   
 
M.  Quantitative Real-Time PCR of Genes 
 For mRNA quantification within in vitro and in vivo studies, total RNA from 
SAECs and mice lungs were isolated using mini RNeasy RNA extraction kit 
(Qiagen, Valencia, CA, USA) (76).  Analysis of the RNA purity and concentration 
was assessed using the Nano Drop ND-1000 (Thermo Scientific, Wilmington, 
DE, USA) (76).  qScript cDNA SuperMix (Quanta Biosciences Inc., Foster City, 
CA, USA) was used to synthesize cDNA using 25 ng of total RNA, as indicated 
by the manufacturer’s protocol.  Reverse transcription and real-time PCR was 
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performed on Applied Biosystems 7500, as suggested by manufacturer’s 
instructions, to assess mRNA expression levels with taqman gene expression 
mastermix (Applied Biosystems Life Technologies, Grand Island, NY, USA).   
The process of cDNA amplification occurred using 2 μL of cDNA which was 
amplified for 40 cycles at 95°C for 15 seconds, 60°C for 1 minute, and 72°C for 
30 seconds.  Primers for CD55, CA9, β-actin were purchased as follows: mouse 
CD55, Mm00438377_m1 taqman primer (Applied Biosystems Life Technologies, 
Grand Island, NY, USA); mouse CA9, Mm00519870_m1 Taqman primer 
(Applied Biosystems Life Technologies, Grand Island, NY, USA); mouse β-actin, 
Mm00607939_s1 taqman primer (Applied Biosystems Life Technologies, Grand 
Island, NY, USA); human CD55, Hs00892618_m1 taqman primer (Applied 
Biosystems Life Technologies, Grand Island, NY, USA); human CA9, 
Hs00154208_m1 taqman primer (Applied Biosystems Life Technologies, Grand 
Island, NY, USA);  human β-actin, Hs01060665_g1 taqman primer (Applied 
Biosystems Life Technologies, Grand Island, NY, USA), and eukaryotic 18S 
ribosomal RNA, Hs99999901_s1 (Applied Biosystems Life Technologies, Grand 
Island, NY, USA) for endogenous control.  The type of endogenous control 
chosen depended on its availability at the time of mRNA analysis.  For analysis 
of the relative expression of target genes, each sample was ran in triplicates.  β-
actin served as the endogenous control, and normalization of the cycle threshold 
(Ct) values were obtained using the 2-ΔΔCt method (76).  Transcripts and mRNA 
are used interchangeably in the results section.    
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N.  Immunohistochemistry (IHC) Analysis of Mice Lungs 
 Mice lungs were perfused, inflated, and fixed with neutral buffered 
formalin.  These formalin-fixed lungs were paraffin-embedded and sectioned into 
4μM tissue sections (prepared at Indiana University School of Medicine).  For 
CD55 staining of mice lungs, the tissue sections underwent process of de-waxing 
and rehydration.  Antigen retrieval was obtained by incubating in rodent 
decloaker (Biocare Medical, Concord, CA, USA) at 95°C for 40 minutes in a 
pressure cooker (Biocare Medical, Concord, CA, USA).  This revealed epitopes 
on the lungs for antibody binding during the staining procedure.  To prevent non-
specific antibody binding during staining, the sections were blocked with 3% 
hydrogen peroxide followed by blocking with rodent block M (Biocare Medical, 
Concord, CA, USA) for 10 minutes and 30 minutes, respectively.  Staining of 
CD55 was achieved by incubating the sections with 1:100 dilution of rabbit anti-
human CD55 (sc9156), (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 hour 
at room temperature.  Following the primary antibody incubation, tissue sections 
were washed and, subsequently, incubated with the rabbit on rodent HRP 
secondary antibody (Biocare Medical, Concord, CA, USA) for 20 minutes.  CD55 
staining was developed by incubating the sections with immPACT DAB 
peroxidase substrate (Vector Laboratories, Burlingame, CA, USA) for 1 minute 
and 30 seconds, followed by counter-staining with Gills hematoxylin (Vector 
Laboratories, Burlingame, CA, USA).   Similar procedure was used for CRRY 
staining but the antibody used was the following: CRRY (Santa Cruz 
Biotechnology, Dallas, TX, USA (M180) (sc-30214).   
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For HIF-1α staining, 4-μm sections of formalin-fixed paraffin-embedded 
mouse lung sections were de-paraffinized and rehydrated.  The sections were 
stained with HIF-1α primary antibody at 1:100 dilution for 30 minutes (NB.100-
479, Novus Biologicals, Littleton, CO, USA).  Antigen retrieval was achieved by 
Dako’s ‘PT Module’ (Dako North America Inc., Carpinteria, CA, USA) with their 
high pH-Target Retrieval Solution using Dako’s Flex+Mouse avidin–biotin system 
(Dako North America Inc., Carpinteria, CA, USA).  This process involved 
incubation with Flex+M linker (Dako North America Inc., Carpinteria, CA, USA), 
and Flex-HRP (Dako North America Inc., Carpinteria, CA, USA) for 30 minutes 
each.  Three wash steps in Dako TBS wash buffer were performed between 
each step.  A 10 minute incubation with HRP-conjugated to the final reagent was 
used to develop the brown diaminobenzidine chromogen (Dako North America 
Inc., Carpinteria, CA, USA).  The sections were counter-stained using 
hematoxylin (Thermo Fisher Scientific, Rockford, IL, USA).  HIF-1α staining was 
performed at Indiana University department of pathology and laboratory 
medicine.    
Images of the stained mice lung sections were visualized and captured 
using whole slide digital imaging system (Aperio Scan Scope CS Systems, Vista, 
CA, USA).  The system imaged all slides at 20x or 10x. 
 
 IHC Quantification  
IHC staining was quantified using Aperio Scanscope (ImageScope) 
11.2.0.780 imaging software (Leica Biosystems, Buffalo Grove, IL, USA).  The 
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positive pixel count algorithim for image quantification were selected on whole 
lung or airways, and analyzed as previously described (76).    
 
O.  C3a and C5a Enzyme-Linked Immunosorbant Assay (ELISA)  
 Complement activation was assessed by measuring C3a (MBS703819 
MyBioSource Inc., San Diego, CA, USA), and C5a (MBS700538 MyBioSource 
Inc., San Diego, CA, USA) levels in mice BALF by ELISA, as indicated by 
manufacturer’s instructions.  For detection of activated complement proteins, 
these assays utilized the quantitative sandwich enzyme immunoassay approach.    
The ELISA plate was read at 450 nm on a Spectra Max Plus (Molecular Devices, 
Sunnyvale, CA, USA).  Analysis of the results were performed on Softmax Pro 
3.1.2 software (Molecular Devices, Sunnyvale, CA, USA).    
 
P.  Statistical Analysis 
Statistical analysis of all the data were performed using GraphPad Prism 4 
Software (GraphPad Prism Software, San Diego, CA, USA).  One-way ANOVA 
with Bonferroni post-test, or two-tailed paired t-test, and unpaired t-test were 
used for statistical analysis.  Data are expressed as mean + standard error mean 
(SEM).  Statistical significance was observed when p<0.05.    
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III.  RESULTS 
A.  Part I:  Hypoxia Induces Expression of HIF-1α and CA9, An Indicator of 
HIF-1α Transcriptional Activity  
Expression of HIF-1α is Induced in Hypoxic Human SAECs 
The onset of hypoxia in several cells and tissues initiates the induction of 
HIF-1α to adapt to conditions with insufficient oxygen levels (134).  While up-
regulation of HIF-1α in hypoxic environment is widely studied in several 
pulmonary cells (183), the induction of this key hypoxic regulator has not been 
reported in vitro in human SAECs.  Thus, to determine whether hypoxic SAECs 
stimulate HIF-1α expression, western blot analysis was performed, and 
antibodies against HIF-1α were used to probe for its expression.  A time-
dependent induction of HIF-1α expression was observed in hypoxic SAECs, with 
significantly higher expression achieved within 6 hours of hypoxia (1% O2) 
(Figure 20A, B, p<0.05).    
 
Increased Expression of CA9, An indicator of HIF-1α Transcriptional Activity in 
Hypoxic SAECs 
 While figure 20A, B showed induction of HIF-1α in hypoxic SAECs, its 
functional activity as a transcription factor was not assessed.  Therefore, to 
confirm that the presence of HIF-1α in hypoxic SAECs correlated with its 
functional characteristic as a transcription factor, mRNA quantification of CA9 
was assessed (144), (146).  Transcript levels for CA9  in these specific SAEC 
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donors were elevated by 16 hours of hypoxia, with statistical significance being 
observed at 16-72 hours of hypoxia (Figure 20C, p<0.05, p<0.01).  This interval 
between induction of HIF-1α and increase in CA9 transcripts, may correspond to 
the time it takes for the stabilized HIF-1α to translocate into the nucleus, to direct 
transcriptional activation of CA9 (144), (146).    
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Figure 20.  Hypoxic SAECs Induce HIF-1α Expression.  SAECs were stimulated 
with hypoxic conditions by exposure to 1% O2 for various time-points.  Cells 
exposed to normoxia (21% O2) were controls.  (A) Protein lysates of hypoxic 
SAECs were probed for expression of HIF-1α.  Lamin β1 as an internal loading 
control.  (B) Densitometry analysis indicated significant up-regulation of HIF-1α 
by 6h of hypoxia vs normoxic (0h) conditions.  Data are representative of 
means+SEM, n=5, *p<0.05 vs normoxia; One-Way ANOVA with Bonferroni post-
test.  (C) Quantification of CA9 mRNA showed an induction with increasing 
hypoxic exposure compared to normoxia.  β-actin was used as the loading 
control.  Data represent mean+SEM, n=3, *p<0.05 or **p<0.01 vs normoxia; 
One-Way ANOVA with Bonferroni post-test.    
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Hypoxia Induces CA9 Gene Expression in Mice Lungs 
 
Induction of HIF-1α within hypoxic lungs was assessed in vivo by exposing 
C57BL/10 male mice to 10% O2 for 24 hours.  Animal studies required a gradual 
decrease in oxygen levels over a 24 hour period to 10% O2 to protect against 
lethal side effects mediated by the rapid decline  in oxygen (184), (185).  Due to 
the short-half-life of HIF-1α protein, and the gradual gradient change in the 
oxygen levels, expression of HIF-1α may be readily degraded, thus, making its 
expression difficult to assess in our in vivo studies.  Therefore, expression of 
CA9, an indicator of HIF-1α transcriptional activity, was analyzed in whole lung 
homogenates of hypoxic mice.  CA9 transcripts increased in 24 hour hypoxic 
mice lungs, compared to lungs of mice in normoxic control conditions (Figure 21, 
p<0.05).    
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Figure 21.  In Vivo Hypoxia Results In Induction Of CA9 In Mice Lungs.  (A) CA9 
was induced at the mRNA level in lungs of 24h hypoxic mice compared to 
normoxic control mice.  β-actin was used as the loading control.  Values 
represent mean+SEM; n>4; *p<0.05 vs controls; two-tailed unpaired t-test.    
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B.   Part II: HIF-1α Dependent Down-regulation of CD55 in Airway   
Epithelium 
 
CD55 Expression is Down-regulated in Hypoxic Human SAECs 
To determine whether hypoxic conditions correlate with CD55 down-
regulation in these SAECs, CD55 transcript and protein expression were 
assessed in hypoxic SAECs (1% O2) using reverse transcription-polymerase 
chain reaction (RT-PCR), and western blot analysis, respectively.  CD55 
transcripts were down-regulated within 6 hours of hypoxia in the SAECs, 
compared to the control normoxic SAECs (Figure 22A, p<0.05).  Notably, the 
transcriptional repression of CD55, and the induction of HIF-1α occurred at the 
same time point in these hypoxic SAECs (Figure 20A and Figure 22A).  These 
data suggest that hypoxia-induced HIF-1α may correlate with CD55 down-
regulation in SAECs.  While CD55 transcript down-regulation occurred as early 
as 6 hours post-hypoxia, down-regulation of CD55 protein expression was not 
observed until 72 hours of hypoxia for these particular donors (Figure 22B, C, 
p<0.05).   
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Figure 22.  Hypoxic SAECs Down-regulate CD55 Expression.  (A) CD55 
transcript levels were significantly down-regulated by 6h hypoxia compared to the 
controlled normoxic conditions.  β-actin was used as the loading control.  Values 
represent means+SEM; n=3; *p<0.05 vs normoxia; One-Way ANOVA with 
Bonferroni post-test.  (B) Protein lysates of hypoxic SAECs were probed for 
expression of CD55 in hypoxic SAECs.  Vinculin was used as internal loading 
control.  (C) Densitometry analysis indicated significant down-regulation of CD55 
protein by 72h of hypoxia vs normoxic conditions.  Data represent mean+SEM, 
n=3, *p<0.05 vs normoxia; One-Way ANOVA with Bonferroni post-test.   
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Differential Regulation of CD46 mRNA and Protein in Hypoxic Human SAECs 
 
 
To assess if hypoxia mediated down-regulation of membrane-bound CRP 
was only specific to CD55 or if this phenomenon was also observed on other 
membrane-bound CRPs that target C3 and C5 convertases, we assessed the 
expression of CD46 in hypoxic human SAECs.  CD46 mRNA levels are down-
regulated by 8 hours of hypoxia on SAECs compared to normoxic controls 
(Figure 23A, p<0.01).  On the contrary, CD46 protein expression was not down-
regulated even at longer hypoxic exposures (Figure 23B).  Thus was further 
confirmed by densitometry analysis of these western blots which showed no 
statistical significant difference in CD46 expression between normoxic controls 
and various time-points for hypoxic exposures (Figure 23C, n. s.) 
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Figure 23.  Hypoxic SAECs Down-regulate CD46 mRNA Expression. 
(A) CD46 mRNA levels are down-regulated in hypoxic SAECs.    
Values represent means+SEM; n=3; **p<0.01 vs normoxia; One-Way ANOVA 
with Bonferroni post-test.  (B) CD46 expression was probed in hypoxic SAECs.  
Vinculin was used as the loading control.  (C) Densitometry analysis show no 
statistical significant difference between any groups when compared to CD46 
expression in normoxic SAECs.  Data represents mean+SEM; n=3; n. s. One-
Way ANOVA with Bonferroni post-test.    
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Down-regulation of CD55 is Observed in Hypoxic Mice Lungs 
 To correlate the down-regulated CD55 expression observed in hypoxic 
SAECs with our in vivo model, we analyzed CD55 expression in C57BL/10 mice 
exposed to hypoxic environment for 24 hours.  Significant down-regulation of 
CD55 transcripts (Figure 24A, p<0.01) and protein expression (Figures 24B, C, 
p<0.01) were observed in whole lung homogenates of mice exposed to 24 hours 
of hypoxia compared to lung homogenates of normoxic mice.  IHC analysis was 
performed to further confirm that the observed CD55 down-regulation was 
occurring within the hypoxic airway epithelium of these mice, compared to the 
CD55 expression present in the airway epithelium of normoxic mice (Figure 
24D).  Quantification of the IHC analysis show CD55 down-regulation on 
C57BL/10 hypoxic mice airways compared to the normal control mice airways 
(Figure 24E, p<0.05) 
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Figure 24.  In Vivo Hypoxia Results In CD55 Down-regulation In Mice Lungs.  (A) 
CD55 transcript levels were significantly down-regulated in 24h hypoxic mice 
lungs compared to lungs of normoxic control mice.  β-actin was used as internal 
loading control.  Values represent means+SEM; n>6; **p<0.01 vs controls; two-
tailed unpaired t-test.  (B) CD55 expression was probed for CD55 in lung 
homogenates of 24h control and hypoxic mice.  β-actin was used as the loading 
control.  (C) Densitometry analysis depict statistically significant down-regulation 
of CD55 in 24h hypoxic mice lungs compared to controls.  Data represents 
mean+SEM; n=4; **p<0.01 vs control mice; two-tailed unpaired t-test.  (D) IHC 
analysis show CD55 down-regulation in 24h hypoxic mice airways compared to 
control mice.  (E) Quantification of IHC shows CD55 down-regulation on hypoxic 
mice airway epithelium.  Values represent mean+SEM; n=8; *p<0.05 vs control 
mice; two-tailed unpaired t-test.   
 
CD55 In 
Control Airways 
Controls Hypoxia Mice (24h)
0.0
0.5
1.0
**
C
D
55
 F
ol
d 
C
ha
ng
e
N
or
m
al
iz
ed
 to
E-A
ct
in
CD55  
(70 kDa) 
A 
C 
D 
B 
CD55 24h 
Hypoxic Airways      IgG Control Airways 
Control Mice   Hypoxia (24h) 
 1     2     3     4    1     2     3    4 
β-actin 
(42 kDa) 
Controls Hypoxia Mice (24h)
0.0
0.5
1.0 **
C
D
55
 D
en
si
to
m
et
ry
 (A
.U
.)
N
or
m
al
iz
ed
 to
 V
in
cu
lin
E 
Controls Hypoxic Mice (24h)
0
10
20
30
40
50
60
*
C
D
55
  %
 P
os
iti
vi
ty
 93 
 
Differential Regulation of CRRY mRNA and Protein Observed in Hypoxic Mice 
Lungs 
 Similar to in vitro CD46 data, human orthologue of CRRY, C57BL/10 mice 
lungs that are hypoxic for 24 hours show CRRY mRNA down-regulation (Figure 
25A, p<0.05).  However, protein expression of CRRY remains unchanged 
compared to CRRY expression in normal control C57BL/10 lungs (Figure 25B).  
This was further confirmed by IHC quantification, which showed no statistical 
significance in CRRY expression between 24 hours hypoxic C57BL/10 mice 
lungs and normal control lungs (Figure 25C, p= n. s.).    
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Figure 25.  Hypoxic Mice Lungs Show Down-regulation Of CRRY Transcripts.   
(A) CRRY transcripts are down-regulated in lungs of hypoxic (24h) C57BL/10 
mice vs controls (normoxic mice).  Data represents mean+SEM; n>6; **p<0.05 vs 
control mice; two-tailed unpaired t-test.  (B) IHC quantification shows that CRRY 
protein expression in hypoxic (24h) C57BL/10 mice airways are not altered 
compared to control airways (normoxic mice).  Data represents mean+SEM; n=3; 
n. s. two-tailed unpaired t-test.   
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Hypoxia Does Not Result in CD55 and CRRY Down-regulation in C57BL/6 Mice 
Lungs   
 To assess if hypoxia resulted in CD55 or CRRY down-regulation in 
C57BL/6 mice lungs like it did in C57BL/10 mice lungs, expression of CD55 and 
CRRY were assessed by IHC in C57BL/6 mice lungs exposed to 24 hours of 
hypoxia (Figure 26).  Compared to normal control C57BL/6 mice lungs 
expression of CD55 and CRRY did not change in 24 hour hypoxic C57BL/6 mice 
lungs (Figures 26A, B).  IHC quantification of CD55 and CRRY further confirmed 
that there was no statistical significance between normal control C57BL/6 mice 
lungs or 24 hour hypoxic mice lungs of the same strain (Figures 26C, D).  
Transcript levels for CD55 and CRRY were not assessed in these mice strains.    
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Figure 26.  Hypoxia In C57BL/6 Mice Has No Effect On CD55 Or CRRY In The 
Lungs.  (A) IHC analysis of C57BL/6 hypoxic (24h) lungs show no change in 
CRRY expression compared to normal (naïve) controls.  (B) IHC analysis of 
C57BL/6 hypoxic (24h) lungs show no change in CD55 expression compared to 
normal (naïve) controls.  (C) Quantification of CRRY IHC in hypoxic (24h) 
C57BL/6 mice airways shows no change.  Data represents mean+SEM; n=4; n.s.  
two-tailed unpaired t-test.  (D) IHC quantification shows that CD55 expression in 
hypoxic (24h) C57BL/6 mice airways are not altered compared to control airways 
(normoxic mice).  Data represents mean+SEM; n=4; n. s. two-tailed unpaired t-
test.   
 
 
 
Naive C57BL/6 
Mouse Lung CD55 
 C57BL/6 24h Hypoxia 
Mouse Lung CD55 
Naive C57BL/6 
Mouse Lung IgG 
A 
Naive C57BL/6 
Mouse Lung CRRY 
Naive C57BL/6 
Mouse Lung IgG 
 C57BL/6 24h Hypoxia 
Mouse Lung CRRY 
 B 
Controls (Normals) Hypoxia Mice (24h)
0
10
20
30
40
50
60
70
80
90
100 n. s.
C
D
55
  %
 P
os
iti
vi
ty
Controls (Normals) Hypoxia Mice (24h)
0
10
20
30
40
50
60
70
80
90
100
n. s.
C
R
R
Y 
%
 P
os
iti
vi
ty
 C  D 
 97 
 
In Vivo, CD55 Down-regulation Results in Local Complement Activation 
 To determine if the observed down-regulation of CD55 in hypoxic mice 
lungs led to complement activation, we assessed local complement levels in 
hypoxic mice versus normoxic control mice.  Down-regulation of CD55 on airway 
epithelium of 24 hour hypoxic mice, resulted in complement activation as 
observed by increased C3a levels in BALF of hypoxic mice compared to control 
mice (Figure 27, p<0.05).  Thus, suggesting a correlation between airway 
epithelial CD55 down-regulation and local complement activation as indicated by 
C3a levels in BALF.  
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Figure 27.  CD55 Down-regulation In Hypoxic Mice Results In Local Complement 
Activation.  C3a levels in BALF of control or 24h hypoxic mice Values represent 
mean+SEM; n=3; *p<0.05 vs controls; two-tailed unpaired t-test.    
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C.  Part III: Inhibition of HIF-1α in Hypoxic Conditions Restores CD55 
Expression 
Chetomin Mediated HIF-1α Inhibition Restores CD55 Expression in Hypoxic 
Human SAECs 
 Due to evidence for HIF-1α regulating CD55 expression in hypoxic in vitro 
and in vivo studies being only a correlation, we investigated the effects of 
pharmacological HIF-1α inhibition on CD55 expression during hypoxia.  
Following a 2 hour pre-treatment of SAECs with the HIF-1α inhibitor, chetomin, 
the cells were exposed to hypoxic conditions (1% O2) for either 6 or 24 hours for 
RNA or protein analysis of CD55, respectively.  Quantification of CD55 mRNA in 
hypoxic conditions with vehicle control showed down-regulation within 6 hours, 
compared to the normoxic controls (Figure 28A, p<0.05).  Optimal dosing for 
chetomin mediated effects on hypoxic SAECs was confirmed in preliminary 
studies (data not shown).   Compared to untreated cells, chetomin (100nM) 
recovered CD55 transcripts in SAECs exposed to 6 hours of hypoxia (Figure 
28A, p<0.001).  Contrary to the CD55 protein down-regulation observed at 72 
hours of hypoxia (Figures 22B, C),   a decrease in CD55 protein expression was 
observed at 24 hours of hypoxia in these and succeeding experiments, which 
may be attributed to donor-dependent variability of the SAECs.  However, 
chetomin treatment restored expression of CD55 in 24 hour hypoxic SAECs 
compared to hypoxic SAECs in absence of chetomin treatment (Figures 28B, C, 
p<0.05).    
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Figure 28.  Chetomin Mediated HIF-1α Inhibition Restores CD55 Expression In 
Hypoxic SAECs.  (A) CD55 transcripts were restored in chetomin (100nM) 
treated cells exposed to 6h hypoxia compared to 6h hypoxic cells in absence of 
chetomin or in normoxia.  Values represent mean+SEM; n=3; *p<0.05 vs 
nomoxia, or ***p<0.001 vs 6h vehicle control in hypoxia; One-Way ANOVA with 
Bonferroni post-test.  (B) Protein lysates were probed for expression of CD55 in 
normoxic SAECs and in the presence or absence of 100nM chetomin in 24h 
hypoxic SAECs.  Vinculin was used as internal loading control.  (C) Densitometry 
analysis indicated significant down-regulation of CD55 in 24h hypoxia compared 
to normoxic levels.  CD55 expression on SAECs was recovered in 24h hypoxic 
SAECs treated with chetomin (100nM) compared to hypoxic SAECs in absence 
of chetomin stimulation.  Data represent mean+SEM, n=3, *p<0.05 vs normoxia 
or 24h hypoxia; One-Way ANOVA with Bonferroni post-test.    
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CA9, An Indicator of HIF-1α Transcriptional Activity, is Down-regulated in 
Chetomin Treated Hypoxic Human SAECs.    
Mechanistically, chetomin functions by inhibiting HIF-1α mediated 
transcriptional activation, while having no affect on the stabilization of HIF-1α 
protein.  This pharmacological inhibition by chetomin involves disruption of the 
interaction between HIF-1α and the co-activator complex with the HREs located 
in the promoter regions of HIF-1α dependent genes (186), resulting in chetomin-
mediated transcriptional repression of HIF-1α dependent genes (186).  Thus, to 
confirm the HIF-1α specificity of chetomin, we analyzed the transcript levels  of 
CA9 an indicator of HIF-1α transcriptional activity (187), (188), which is an 
indicator of HIF-1α transcriptional activity.  Treatment with 100 nM chetomin in 6 
hour hypoxic SAECs resulted in down-regulation of CA9 transcripts compared to 
6h hypoxic SAECs in the absence of chetomin (Figure 29, p<0.05), confirming 
that effects of chetomin are HIF-1α specific.    
 
 
 
 
 
 
 
 102 
 
 
 
 
 
 
 
 
Figure 29.  Transcripts Of CA9 Are Down-regulated In Chetomin Treated Hypoxic 
SAECs.  Transcript levels for CA9 were increased in 6h hypoxic SAECs 
compared to those in normoxia, but were down-regulated in chetomin (100nM) 
treated cells compared to those in 6h hypoxic SAECs.  β-actin was used as 
internal loading control.  Values represent mean+SEM; n=3; *p<0.05 vs 6h 
hypoxia with vehicle control; One-Way ANOVA with Bonferroni post-test.    
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Chetomin Mediated HIF-1α Inhibition Restores CD55 Expression in Hypoxic Mice 
Lungs 
 Intrapulmonary HIF-1α inhibition, in vivo, was achieved by intratracheal 
instillation of 1mg/ml chetomin or vehicle control in 24 hour hypoxic mice.  
Compared to CD55 down-regulation in  control or vehicle control mice lungs, 
CD55 expression was restored in chetomin treated hypoxic mouse lung 
homogenates (Figures 30A, B, p<0.01).  Because CD55 is being down-regulated 
on the airway epithelium of these hypoxic mice (Figure 24D), we utilized IHC 
analysis to further confirm that chetomin mediated recovery of CD55 occurred on 
airway epithelium during in vivo hypoxic conditions.  Airway epithelial CD55 
recovery was observed in chetomin treated hypoxic mice compared to 24 hour 
hypoxic mice treated with the appropriate vehicle control (Figure 30C).    
 
CA9 is Down-regulated in Lungs of Chetomin Instilled Hypoxic Mice 
 To confirm the HIF-1α specific effects of chetomin in vivo, mRNA 
quantification of CA9 was performed in 24 hour hypoxic mice lungs instilled with 
chetomin or the appropriate vehicle control.  Interestingly, these studies indicate 
that CA9 transcripts were elevated in 24 hour hypoxic mice lungs compared to 
the control lungs of normoxic mice (Figure 30D, p<0.01).  However, in presence 
of chetomin, CA9 transcripts were reduced in lung homogenates of these 24 hour 
hypoxic mice compared to control mice lungs or  lungs of hypoxic mice instilled 
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with vehicle control (Figure 30D, p<0.01).  Thus, confirming the role of chetomin 
in regulating the transcriptional activity of HIF-1α.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.  Chetomin Recovers CD55 Expression In Hypoxic Mice Lungs.  (A) 
CD55 expression was probed 24h hypoxic mice lungs intratracheally instilled with 
chetomin (1mg/ml) or with vehicle control.  Vinculin was the internal loading 
control.  (B) Densitometry analysis show CD55 down-regulation in 24h hypoxic 
mice lungs instilled with chetomin (1mg/ml) vs vehicle controls.  Values represent 
mean+ SEM, n=4, **p<0.01 vs vehicle control; two-tailed unpaired t-test.  (C) IHC 
data show CD55 down-regulation in chetomin instilled 24h hypoxic mice lungs vs 
vehicle control hypoxic mice lungs.  (D) CA9 transcripts were down-regulated in 
chetomin instilled 24h hypoxic mice lungs compared to vehicle control.  Values 
represent mean+SEM; n>3; **p<0.01 vs control or vehicle control; One-Way 
ANOVA with Bonferroni post-test.    
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HIF-1α Expression is Silenced in HIF-1α siRNA Transfected Hypoxic Human 
SAECs 
Chetomin provided indirect evidence of HIF-1α regulating CD55 on airway 
epithelium.  Therefore, inhibition of HIF-1α via specific mechanisms such as the 
use silencing RNA (siRNA) were exploited.  Prior to the assessment of CD55 
expression, control experiments were performed to determine the efficacy of HIF-
1α siRNA.  Following transfection of SAECs with 50nM HIF-1α siRNA or 50nM 
control siRNA, the cells were exposed to 6 hours of hypoxia.  HIF-1α expression 
was induced in 6 hour hypoxic SAECs transfected with control siRNA compared 
to its expression in normoxic SAECs (Figures 31A, B, p<0.05).  However, SAECs 
transfected with HIF-1α siRNA showed a significant decrease in HIF-1α 
expression when compared to normoxic SAECs or to control siRNA transfected 
hypoxic SAECs (Figure 31B, p<0.05).   
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Figure 31.  Silencing HIF-1α In Hypoxic SAECs.  (A) HIF-1α protein expression is 
silenced in 6h hypoxic SAECs transfected with 50nM HIF-1α siRNA compared to 
the induced HIF-1α expression in 6h hypoxic SAECs with control siRNA (50nM) 
and HIF-1α expression present in normoxic basal hypoxia.  Lamin β1 was used 
as internal loading control.  (B) Densitometry analysis indicated significant down-
regulation of HIF-1α in SAECs transfected with HIF-1α siRNA (50nM) under 6h 
hypoxia compared to normoxic basal levels in SAECs or control siRNA (50nM) in 
hypoxic SAECs.  Data represent mean+SEM, n=3, *p<0.05 vs normoxia or 
control siRNA in 24h hypoxia; One-Way ANOVA with Bonferroni post-test.    
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CA9 Expression is Repressed in HIF-1α siRNA Transfected Hypoxic Human 
SAECs 
Silencing of HIF-1α via siRNA in 6 hour hypoxic SAECs was further 
confirmed by quantifying CA9 mRNA.  CA9 transcripts were reduced in 6 hour 
hypoxic SAECs transfected with HIF-1α siRNA compared to normoxic SAECs or 
6 hour hypoxic SAECs transfected with or without the control siRNA (Figure 32, 
p<0.01).  Due to induction of HIF-1α occurring at 6 hours of hypoxia in SAECS, 
longer hypoxic exposure may be necessary for CA9 transcription in SAECs 
(Figure 20C).  Thus, CA9 transcript levels remain at basal levels in normoxic and 
6 hour hypoxic SAECs with or without control-siRNA.  The specificity of the HIF-
1α siRNA was confirmed by data showing that silencing HIF-1α in 6 hour hypoxic 
SAECs down-regulated CA9 transcript levels (Figure 32, p<0.01) compared to 
normoxic SAECs or 6h hypoxic SAECs transfected with or without control siRNA.    
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Figure 32.  Silencing HIF-1α In Hypoxic SAECs Results In CA9 Down-regulation.   
CA9 transcript levels were down-regulated in HIF-1α siRNA transfected 6h 
hypoxic SAECs compared to 6h hypoxic SAECs with or without control siRNA 
transfection.  β-actin was used as internal loading control.  Values represent 
mean+SEM; n=3; **p<0.01 vs nomoxia, 6h hypoxia, or control siRNA; One-Way 
ANOVA with Bonferroni post-test.   
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Silencing HIF-1α in Hypoxic SAECs Restores CD55 Expression 
 To assess effects of silencing HIF-1α on CD55 expression in hypoxic 
SAECs, cells were exposed to 6 hours of hypoxia following transfection with 
50nM HIF-1α siRNA or control siRNA.  Compared to CD55 transcript levels in 
normoxic cells or hypoxic cells transfected with the control siRNA, an increase in 
CD55 transcripts were observed in SAECs where HIF-1α is silenced within 6 
hours of hypoxia  (Figure 33A, p<0.05).  Interestingly, CD55 protein expression 
was also restored in hypoxic SAECs where HIF-1α was silenced compared to 
normoxic control cells or hypoxic cells transfected with control siRNA (Figures 
33B, C, p<0.05).    
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Figure 33.  Silencing HIF-1α In Hypoxic SAECs Restores CD55 Expression.  (A) 
CD55 transcript levels were recovered in HIF-1α siRNA (50nM) transfected 6h 
hypoxic SAECs compared to 6h hypoxic SAECs in the presence or absence of 
control siRNA (50nM).  β-actin was used as internal loading control.  Values 
represent mean+SEM; n=3; *p<0.05 vs nomoxia, 6h hypoxia, or controls siRNA; 
One-Way ANOVA with Bonferroni post-test.  (B) CD55 protein expression was 
probed for in normoxic, or 24h hypoxic HIF-1α siRNA (50nM) or control siRNA 
(50nM) transfected SAECs.  Vinculin was used as internal loading control.  (C) 
Densitometry analysis depict recovery of CD55 protein in  24h HIF-1α siRNA 
(50nM) transfected SAECs compared to control siRNA (50nM) or normoxic basal 
levels.  Values represent mean+SEM; n=3; *p<0.05 vs nomoxia, 24h hypoxia, or 
controls siRNA; One-Way ANOVA with Bonferroni post-test.   
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HIF-1α Expression is Knocked-down in Mice Lungs After Intratracheal Instillation 
of HIF-1α siRNA 
We also silenced HIF-1α in our hypoxic in vivo model to investigate its 
effect on CD55 expression within mice lungs.  To knock-down HIF-1α expression 
specifically in the lungs, intratracheal instillation of HIF-1α siRNA or control 
siRNA was performed 72 hours prior to their 24 hour exposure to hypoxia (10% 
O2).  Efficacy of HIF-1α siRNA was confirmed by western blot analysis of hypoxic 
mice lungs (Figure 34A).  Protein quantification of HIF-1α through densitometric 
analysis show HIF-1α silencing in 24 hour hypoxic mice lungs instilled with HIF-
1α siRNA compared to the lungs instilled with control siRNA.  (Figures 34A, B, 
p<0.01).  IHC analyses was performed to confirm the down-regulation of HIF-1α 
in the airway epithelium of these 24 hour hypoxic mice instilled with HIF-1α 
siRNA (Figure 34C).  Modest down-regulation of HIF-1α is observed in airways of 
hypoxic mice instilled with HIF-1α siRNA compared to controls (Figure 34C) but 
IHC readout is not reliable due to the patchy and location-dependent down-
regulation of HIF-1α observed in these mice lung sections. Therefore, a more 
reliable readout to confirm HIF-1α silencing in vivo is needed.  This patchy nature 
of HIF-1α induction and down-regulation observed within the hypoxic mice lungs, 
may be attributed to the temporal variability in stabilization of HIF-1α, and other 
HIF isoforms present among various cell types in the lung (189), (174).    
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Figure 34.  Intratracheal Silencing Of HIF-1α In Hypoxic Mice Lungs.  (A) HIF-1α 
expression was probed for in lung homogenates of 24h hypoxic mice 
intratracheally instilled with HIF-1α siRNA (50μg) or control siRNA (50μg).  Lamin 
β1 was used as internal loading control.  (B) Densitometry analysis indicated 
significant down-regulation of HIF-1α in lung homogenates of 24h hypoxic mice 
intratracheally instilled with HIF-1α siRNA (50μg) compared to control siRNA 
(50μg).  Values represent mean+SEM, n=4, **p<0.01 vs control siRNA; two-
tailed unpaired t-test.  (C) IHC analysis show HIF-1α down-regulation in hypoxic 
mice lungs where HIF-1α is silenced compared to control hypoxic mice lungs.    
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CA9 is Down-regulated in HIF-1α Silenced Hypoxic Mice Lungs 
While these in vivo HIF-1α siRNA studies show HIF-1α knock-down via 
western blot analysis, the inconsistent HIF-1α expression observed in IHC data 
implicate the need for a more reliable readout to verify HIF-1α silencing in 
hypoxic condition, in vivo.  Thus, to confirm HIF-1α knockdown in these studies, 
mRNA quantification of CA9, and indicator of HIF-1α transcriptional activity, was 
implemented.  Increase in CA9 transcripts were detected in 24 hour hypoxic mice 
lungs compared to controls (Figure 35, p<0.001), but were down-regulated in 24 
hour hypoxic mice lungs with HIF-1α siRNA compared to control siRNA (Figure 
35, p<0.05).    
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Figure 35.  Silencing HIF-1α Via Intratracheal Instillation Down-regulates CA9 
Transcripts In Hypoxic Mice Lungs.  Transcript levels for CA9 are induced in 
hypoxic mice lungs instilled with control siRNA, but down-regulated in hypoxic 
mice lungs where HIF-1α expression is silenced.  β-actin was used as internal 
loading control.  Data represents mean+SEM, n>3; ***p<0.001 vs controls, 
*p<0.05 vs control siRNA; One-Way ANOVA with Bonferroni post-test.    
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Silencing HIF-1α in Hypoxic Mice Lungs Restores CD55 Expression 
CD55 expression was assessed by western blot analysis on lungs extracts 
of mice intratracheally instilled with either HIF-1α siRNA or control siRNA (Figure 
36A).  CD55 protein expression was significantly restored in hypoxic mice lungs 
instilled with HIF-1α siRNA compared to mice lung homogenates with control 
siRNA (Figure 36B, p<0.05).  Similarly, IHC analysis depict recovery of CD55 
expression occurring, specifically, in the airway epithelium of 24 hour hypoxic 
mice when HIF-1α is silenced (Figure 36C).  Therefore, suggesting an inverse 
regulation between induction of HIF-1α and down-regulation of CD55 in lungs, 
specifically, in the airway epithelium of the lungs, during hypoxia.  Despite the 
recovery of CD55 in HIF-1α silenced mice airway epithelium, complement 
activation still occurred (Figure 37).  C3a levels in BALF were comparable 
between HIF-1α silenced hypoxic mice and hypoxic mice instilled with control 
siRNA (Figure 37).            
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Figure 36.  Intratracheal Silencing Of HIF-1α In Hypoxic Mice Lungs Recovers 
CD55 Expression.  (A) CD55 expression was probed for in lung homogenates of 
24h hypoxic mice intratracheally instilled with HIF-1α siRNA (50μg) or control 
siRNA (50μg).  β-actin was used as internal loading control.  (B) Densitometry 
analysis indicated CD55 was restored significantly in lung homogenates of 24h 
hypoxic mice intratracheally instilled with HIF-1α siRNA (50μg) compared to 
control siRNA (50μg).  Data represents mean+SEM, n=4, *p<0.05 vs control 
siRNA; two-tailed unpaired t-test.  (C) IHC analysis show CD55 down-regulation 
in hypoxic mice lungs where HIF-1α is silenced compared to hypoxic mice lungs 
with control siRNA.    
 
Control siRNA 
(24h Hypoxia)  
HIF-1α siRNA 
(24h Hypoxia)  
1        2       3      4      1       2        3       4 
A 
IgG 
CD55 In 24h Hypoxia 
Control siRNA 
CD55 In 24h Hypoxia  
HIF-1α siRNA 
C 
B 
CD55 
(70 kDa)  
β-actin 
(42  kDa) 
Control siRNA HIF-1D siRNA
0.0
0.5
1.0
*
24h Hypoxia
C
D
55
 D
en
si
to
m
et
ry
 (A
.U
.)
N
or
m
al
iz
ed
 to
 V
in
cu
lin
 118 
 
 
 
 
 
 
 
Figure 37.  CD55 Recovery In HIF-1α Silenced Mice Lungs, Resulted In No 
Change In Local Complement Activation.  C3a levels in BALF of control or 24h 
hypoxic mice Values represent mean+SEM; n>3; no statistical significance (n. s.) 
vs normoxia, hypoxia, or control siRNA; two-tailed unpaired t-test.    
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D.  Part IV: Induction of HIF-1α in Normoxic Conditions Down-regulates 
CD55 Expression 
DMOG Treatment Induces HIF-1α Expression in Normoxic SAECs 
To determine if HIF-1α expression was sufficient for CD55 down-
regulation in the absence hypoxic stimuli, we investigated CD55 expression in 
normoxic SAECs where HIF-1α expression was stabilized with DMOG treatment 
to inhibit the PHD enzymes.  To confirm the HIF-1α specificity of DMOG, control 
experiments were performed to demonstrate that HIF-1α expression was 
stabilized post-DMOG treatment in normoxic SAECs.  Western blot analysis 
confirmed significant induction of HIF-1α in normoxic SAECs treated with 1μM of 
DMOG for 6-24 hours (Figures 38A, B, p<0.05).  Optimal dosing for DMOG 
mediated effects on SAECs for HIF-1α and CD55 expression were verified in 
preliminary studies (data not shown).    
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Figure 38.  Stabilization Of HIF-1α In Normoxic SAECs By DMOG.  (A) DMOG 
(1μM) treated SAECs were probed for HIF-1α protein expression.  Lamin β1 was 
used as internal loading control.  (B) Densitometry analysis indicated significant 
induction of HIF-1α within 6-24h DMOG (1μM) treated SAECs compared to cells 
without DMOG treatment.  Values represent mean+SEM, n=3, *p<0.05 vs non-
treated cells (0hr controls); One-Way ANOVA with Bonferroni post-test.    
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CA9 Expression is Induced in DMOG Stimulated Normoxic Human SAECs 
To verify the HIF-1α activation by DMOG treatment on normoxic SAECs, 
we also quantified CA9 mRNA in these DMOG treated SAECs for 6 hours post-
treatment (Figure 39, p<0.05), and for 24 hours post-treatment (Figure 39, 
p<0.01).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122 
 
 
 
 
 
 
 
 
Figure 39.  DMOG Mediated HIF-1α Stabilization In Normoxic SAECs Induces 
CA9 Transcription.  Transcription levels for CA9 were up-regulated in DMOG 
(1μM) treated SAECs compared to non-treated cells.  β-actin was used as 
internal loading control.  Data represents mean+SEM; n=3; *p<0.05, or **p<0.01 
vs non-treated cells (0hr controls); One-Way ANOVA with Bonferroni post-test.   
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DMOG Mediated HIF-1α Stabilization Under Normoxia Down-regulates CD55 
Expression in SAECs 
 To assess if stabilizing HIF-1α in normoxic SAECs is adequate for CD55 
down-regulation in absence of hypoxic conditions, CD55 expression was 
analyzed in 1μM DMOG-treated normoxic SAECs.  Transcriptional down-
regulation of CD55 was observed following 6 hours of DMOG treatment in 
SAECs compared to the controls (Figure 40A, p<0.01).  However, consistent with 
the longer time-frame required for CD55 protein down-regulation, as seen in our 
in vitro studies, western blot analysis shows  down-regulation of CD55 occurring 
at 24 hours post-1μM DMOG treatment in normoxic SAECs (Figures 40B, C, 
p<0.01).  Therefore, these in vitro DMOG studies suggest that expression of HIF-
1α is sufficient for mediating CD55 suppression in airway epithelial cells, even in 
the absence of an hypoxic environment. 
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Figure 40.  Induction Of HIF-1α In Normoxic SAECs Results In CD55 Down-
regulation.  (A) CD55 transcript levels were down-regulated in 6h DMOG (1μM) 
treated SAECs compared to the non-treated cells (0hr controls).  Data represents 
mean+SEM; n>3; **p<0.01 vs 0h (non-treated cells); One-Way ANOVA with 
Bonferroni post-test.  (B) CD55 protein expression was probed for in DMOG 
(1μM) treated SAECs.  Lamin β1 was used as internal loading control.  (C) 
Densitometry analysis show statically significant CD55 down-regulation by 24h of 
in DMOG (1μM) treated SAECs compared to the non-treated cells (0hr controls).  
Values represent mean+SEM; n=3; **p<0.01 vs non-treated cells (0hr controls); 
One-Way ANOVA with Bonferroni post-test.   
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Intratracheal Instillation of DMOG Stabilizes Lung HIF-1α During Normoxia 
 To address whether presence of HIF-1α in non-hypoxic conditions is also 
sufficient enough to regulate CD55 expression in vivo, intratracheal instillation of 
1mg/ml of DMOG was implemented in normoxic C57BL/10 mice.  Similar to the 
in vitro DMOG studies, HIF-1α specificity of DMOG was confirmed in our in vivo 
model.  Significant stabilization of HIF-1α was observed as early as 6 hours in 
lungs of normoxic mice intratracheally instilled with 1mg/ml DMOG compared to 
normoxic mice instilled with the appropriate vehicle control (Figures 41A, B, 
p<0.05).  To confirm that DMOG mediated-induction of HIF-1α occurred in airway 
epithelium, expression of HIF-1α was assessed by IHC.  Staining data from these 
IHC studies show HIF-1α stabilization in airway epithelium 6 hours post-1mg/ml 
DMOG intratracheal instillation in normoxic mice, compared to its expression in 
airway epithelium of vehicle control mice (Figure 41C).    
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Figure 41.  Intratracheal Induction Of HIF-1α In Normoxic Mice Lungs Down-
regulates CD55 Expression.  (A) HIF-1α expression was probed in lung 
homogenates 6h post mice intratracheal instillation with DMOG (1mg/ml) or 
vehicle control.  Lamin β1 was used as internal loading control.  (B) Densitometry 
analysis indicated significant induction of HIF-1α in lung homogenates of 
intratracheally instilled with DMOG (1mg/ml) or vehicle control.  Values represent 
mean+SEM, n=4, *p<0.05 vs vehicle controls; two-tailed unpaired t-test.  (C) IHC 
analysis indicate induction of HIF-1α in mice airways within 6h post-DMOG 
instillation compared to vehicle control airways.    
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DMOG Induces CA9 In Vivo 
Assessment of CA9, an indicator of HIF-1α transcriptional activity, was 
performed to further confirm HIF-1α activity induced by its stabilization via DMOG 
within normoxic in vivo conditions.  Normoxic mice lungs where HIF-1α was 
stabilized by intratracheal instillation of 1mg/ml DMOG, depict an increase in CA9 
transcripts within 6 hours compared to lungs of mice intratracheally instilled with 
vehicle controls (Figure 42, p<0.05).    
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
 
 
 
 
 
Figure 42.  In Vivo Stabilization Of HIF-1α In Normoxic Lungs Results In 
Induction Of CA9 Transcription.  Transcription levels for CA9 were up-regulated 
in DMOG (1mg/ml) treated SAECs compared to vehicle control cells.  β-actin was 
used as internal loading control.  Data represents mean+SEM; n=3; *p<0.05 vs 
non-treated cells (0hr controls); two-tailed unpaired t-test.   
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Intratracheal Instillation of DMOG Results in Lung CD55 Down-regulation During 
Normoxia  
 We next investigated the role of HIF-1α in regulating CD55 expression 
during normoxia.  Analogous to our in vitro DMOG studies, stabilization of HIF-1a 
via intratracheal instillation of 1 mg/ml DMOG in mice resulted in transcriptional 
down-regulation of CD55 within 6 hours (Figure 43A, p<0.01) in lungs of DMOG 
instilled normoxic mice.  Notably, densitometry analysis of CD55 protein 
expression also show down-regulation in lungs within 6 hours post- DMOG 
instillation in these normoxic mice compared to normoxic mice lungs instilled with 
vehicle control at the same time-point (Figures 43B, C, p <0.01).  Airway 
epithelial specific CD55 suppression was also observed by IHC analysis in these 
DMOG treated mice compared to controls (Figure 43D).  Together, these in vivo 
DMOG studies support the results obtained from DMOG in vitro studies that 
suggest that expression of HIF-1α, a transcription factor potently induced by 
hypoxia, is adequate to modulate airway epithelial CD55 expression in hypoxic, 
as well as, in non-hypoxic conditions.  However, down-regulation of CD55 by 
HIF-1α stabilization in normoxic conditions did not induce local complement 
activation (Figure 44).    
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Figure 43.  Intratracheal Induction Of HIF-1α In Normoxic Control Mice Down-
regulates CD55 Expression In Lungs.  (A) CD55 transcripts were down-regulated 
in mice lungs intratracheally instilled with for 6h DMOG (1mg/ml) compared to 
vehicle controls.  Data represent mean+SEM, n=3, **p<0.01 vs vehicle controls; 
two-tailed unpaired t-test.  (B) CD55 expression was probed in mice lungs 6h 
post intratracheal instillation with DMOG (1mg/ml) or vehicle controls.  Vinculin 
was used as internal loading control.  (C) Densitometry analysis indicated CD55 
down-regulation in mice lungs intratracheally instilled with DMOG (1mg/ml) or 
vehicle controls.  Values represent mean+SEM, n=4, **p<0.01 vs vehicle 
controls; two-tailed unpaired t-test.  (D) IHC shows CD55 down-regulation within 
6h post-DMOG instillation vs vehicle control airways.    
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Figure 44.  Down-regulation Of Airway Epithelial CD55 By DMOG, Does Not 
Result In Local Complement Activation.  C3a levels are not statistically significant 
(n. s.) in BALF of vehicle control or DMOG 1 mg/ml intratracheally instilled mice 
within 6h in normoxia.  Values represent mean+SEM; n>3; n. s. vs vehicle 
control; two-tailed unpaired t-test.    
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Gene Therapy-induced Expression of HIF-1α in SAECs by HIF-1α Adenoviral 
Vector, AdCA5  
Pharmacological stabilization of HIF-1α in normoxic in vitro and in vivo 
conditions, down-regulate CD55.  In a complementary approach, we utilized 
adenoviral vectors to induce constitutive HIF-1α expression in SAECs during 
normoxia.  SAECs were transduced with  an adenoviral vector, AdCA5, 
containing an insert to express constitutively activated HIF-1α (155).  AdLACZ 
was used as the control vector (155).  To confirm that HIF-1α expression was 
stabilized in normoxic SAECs following 50 PFUs/cell transduction of AdCA5, 
western blot analysis was performed.  Compared to the control AdLACZ 
transduced normoxic SAECs, protein quantification of HIF-1α expression through 
densitometric analysis show induction of HIF-1α in AdCA5 transduced normoxic 
SAECs 24 hours post- transduction (Figures 45A, B, p<0.05).   
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Figure 45.  AdCA5 Mediated HIF-1α Induction In  Normoxic SAECs Results In 
CD55 Down-regulation.  (A) AdCA5 (50 PFUs/cell) transduced SAECs for 24h 
were probed for HIF-1α protein expression.  Lamin β1 was used as internal 
loading control.  (B) Densitometry analysis indicated significant induction of HIF-
1α within 24h of AdCA5 transduced SAECs compared to cells with control 
AdLACZ (50 PFUs/cell) transduction.  Values represent mean+SEM, n=3, 
*p<0.05 vs AdLACZ; two-tailed paired t-test.   
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CA9 Expression was Induced in AdCA5 Transduced Normoxic Human SAECs  
CA9 transcripts were assessed to confirm that AdCA5 mediated induction 
of HIF-1α in normoxic SAECs also resulted in HIF-1α transcriptional activity.  
Compared to CA9 transcripts observed in SAECs transduced with control 
adenoviral vector, AdLACZ, AdCA5 transduced normoxic SAECs show increase 
expression of CA9 transcripts.  Thus, confirming that even in normoxic 
conditions, AdCA5 can induce HIF-1α expression which leads to activation of its 
transcriptional activity (Figure 46, p<0.001).    
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Figure 46.  HIF-1α Stabilization By AdCA5 In Normoxic SAECs Induces CA9 
Transcription.  CA9 transcript levels were significantly elevated in normoxic 
SAECs transduced with AdCA5 (50 PFUs/cell) for 24h vs SAECs transduced 
with AdLACZ (50 PFUs/cell).  β-actin was used as internal loading control.   
Values represent mean+SEM; n=3; ***p<0.001 vs AdLACZ; two-tailed paired t-
test.    
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CD55 Expression was Down-regulated in AdCA5 Transduced Normoxic Human 
SAECs 
DMOG provided indirect evidence of HIF-1α regulating CD55 expression 
on airway epithelium, therefore, we also investigated CD55 expression in AdCA5 
transduced normoxic SAECs.  Western blot and densitometric analysis confirmed 
that transduction of normoxic SAECs with 50 PFUs/cell of AdCA5 for 24 hours, 
resulted in CD55 down-regulation compared to its expression in observed in the 
control AdLACZ transduced normoxic SAECs (Figures 47A, B, p<0.05).  
Collectively, these studies demonstrate that induction of HIF-1α, in the presence 
or absence of hypoxia, negatively regulates CD55 expression in airway epithelial 
cells.    
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Figure 47.  AdCA5 Mediated HIF-1α Stabilization Down-regulates CD55 In 
Normoxic SAECs.  (A) CD55 expression was probed for in SAECs transduced 
with AdCA5 (50 PFUs/cell) for 24h.  Vinculin was used as internal loading 
control.  (B) Densitometry analysis show significant down-regulation of CD55 in 
24h SAECs transduced with AdCA5 (50 PFUs/cell) compared to expression in 
AdLACZ (50 PFUs/cell) transduction.  Values represent mean+SEM; n=4; 
*p<0.05 vs AdLACZ; two-tailed paired t-test.    
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IV.  DISCUSSION 
A.  Summary 
The key findings in these in vitro and in vivo studies, highlight the 
importance of HIF-1α in regulating airway epithelial CD55 expression.  As 
indicated in part I and II, induction of HIF-1α coincided with CD55 down-
regulation in hypoxic SAECs, as well as, in hypoxic mice lungs.  Thus, to 
determine if the presence of HIF-1α correlated with suppression of CD55 on 
airway epithelium, HIF-1α expression was manipulated in airway epithelium, and 
CD55 expression was analyzed in vitro and in vivo.  Notably, to confirm that HIF-
1α induced during hypoxia mediates down-regulation of CD55, but not other 
membrane-bound CRPs, we assessed expression of other membrane-bound 
CRPs such as CD46 and CRRY in our hypoxic in vitro and in vivo studies, 
respectively.  While CD46 and CRRY transcript levels were down-regulated in 
vitro and in vivo respectively, neither of them were down-regulated at the protein 
level.  These results suggest that CD46 and CRRY may be differentially 
regulated at the mRNA and protein level in hypoxic conditions.  Another level of 
complexity for CD46 and CRRY regulation may involve the fact that although 
they are functionally and structurally similar, they are not identical which may 
also contribute to their differential regulation along with their location being 
species restricted.  Therefore, our studies primarily focus on CD55 because it is 
affected by hypoxia, and its expression is not species restricted.  Interestingly, 
we also observed difference in CD55 and CRRY expression between two 
different strains of mice.  C57BL/10 mice when exposed to hypoxia for 24 hours 
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had down-regulation of CD55 at the transcript and protein level, but CRRY was 
only transcriptionally down-regulated.  However, when C57BL/6 mice were 
exposed to hypoxia for 24 hours, no change in CD55 or CRRY expression was 
observed on the lungs.   
Experimental findings in part III indicate that inhibiting HIF-1α in hypoxic 
SAECs by chetomin treatment or by transfection of HIF-1α siRNA, resulted in 
recovery of CD55.  Notably, HIF-1α inhibition, in vivo, by intratracheal instillation 
of chetomin or HIF-1α siRNA also restored CD55 expression in hypoxic mice 
lungs.  However, as suggested by part IV, induction of HIF-1α in normoxic human 
SAECs through AdCA5 transduction or treatment with DMOG, resulted in CD55 
down-regulation.  Similarly, in vivo HIF-1α stabilization mediated by intratracheal 
instillation of DMOG, caused CD55 down-regulation in normoxic mice lungs.  To 
confirm HIF-1α specificity of chetomin and DMOG, transcript levels for CA9 was 
assessed.  Due to the short half-life of HIF-1α, CA9 expression was also 
analyzed in the in vivo model to confirm HIF-1α activity.   
Correlation between local complement activation and down-regulation of 
the CRP, CD55, on airway epithelium has been observed in these hypoxic in vivo 
conditions.  Following the exposure of mice to 24 hours hypoxia, airway epithelial 
down-regulation of CD55 and local complement activation was observed in our in 
vivo hypoxic model.  These experimental findings provide insight into HIF-1α 
mediated regulation of CD55.  Although, the precise molecular mechanism by 
which HIF-1α regulates CD55 expression still remains undefined.    
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B.  Cell-specific Effects of HIF-1α Mediated CD55 Regulation 
While numerous studies have tried to elucidate mechanisms and signaling 
pathways that regulate CD55 expression (80), (190), only limited studies have 
focused their investigation on the role of hypoxia, and in particular, the role of 
HIF-1α, in regulating cell surface expression of CD55.  Hypoxia-mediated down-
regulation of CD55 has been identified in other studies with the human neuronal 
cell line, NT2N (191).  However, to the best of our knowledge, this is the first 
study to show HIF-1α mediated negative regulation of CD55 on airway epithelial 
cells.  On the contrary, prior studies by Colgan and Stahls’ group have reported 
HIF-1α or hypoxia-mediated induction of CD55 expression on either human 
colorectal adenocarcinoma cells (80) or human umbilical vein endothelial cells 
(190), respectively.  These contrasting reports on CD55 regulation by HIF-1α or 
hypoxia, may be attributed to the variability associated with the utilization of 
different cell types.  In the current study we have assessed effects of HIF-1α on 
CD55 expression in the context of primary human airway epithelial cells.  
Whereas, prior reports exploited immortalized cell lines or utilized endothelial 
cells for analysis of hypoxia or HIF-1α dependent CD55 expression.  In addition, 
the use of different cell types may add another factor of variability for hypoxia or 
HIF-1α mediated CD55 regulation, because it has been reported that different 
cell types have distinct time-frames during which hypoxia mediated- HIF-1α 
expression is induced (80), (190).  Therefore, it is possible that the differences 
temporal regulation of HIF-1α expression among various cell types can 
differentially regulate CD55.  Other factors that may contribute to the differential 
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CD55 expression observed among our studies and studies reported by Colgan 
(80) or Stahl’s group (190), may involve the amount of oxygen concentration 
used to mimic hypoxia, or the time-frame of hypoxia implemented on these 
various  cell types.  Notably, studies reported by Stahl’s group involve the 
assessment of CD55 under hypoxia and reoxygenated conditions.  The 
involvement of reoxygenation initiates several other signaling pathways and 
mechanisms that may be distinct from those only seen in hypoxic conditions.  
This may result in variability of CD55 expression.  Furthermore, while HIF-1α is 
potently induced by hypoxia, other down-stream signaling cascades such as 
activation of NFkB or MAPK are also initiated and play a pivotal factor in 
regulating responses associated with hypoxia (192), (193).  Collectively, this 
suggests that while studies by Stahl’s group show hypoxia-driven CD55 induction 
on human umbilical vein endothelial cells, they do not specifically illustrate the 
role of HIF-1α in regulating its expression (190).  Additionally, unlike prior studies 
performed by Colgan (80) or Stahl’s group (190), we confirmed the observed 
results from our in vitro data by translating them into in vivo conditions.  Thus, 
demonstrating HIF-1α dependent down-regulation of CD55 in mouse airway 
epithelium.    
 
C.  Potential Role of Other HIF Isoforms in Regulating CD55 
While the focal point of our studies was to understand and elucidate the 
role of HIF-1α in regulating CD55 expression in airway epithelium, other hypoxia 
inducible factor isoforms, such as hypoxia- inducible factors 2 alpha or 3 alpha 
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(HIF-2α and HIF-3α), might also have a role in CD55 regulation.  HIF-1α was the 
primary hypoxia-inducible factor selected to assess CD55 in hypoxic in vitro and 
in vivo conditions, due to its ubiquitous and uniformly inducible nature, as well as, 
the wide array of studies available on its molecular mechanism and regulation 
(134), however, recent advances have highlighted the importance of HIF-2α and 
HIF-3α in hypoxic conditions (194), (175).  Notably, while chetomin and DMOG 
are widely known to target HIF-1α they also have an effect on other HIF isoforms.  
Therefore, the indirect evidence of airway epithelial CD55 expression being 
regulated by chemical inhibitor or stabilizer of HIF-1α such as chetomin or 
DMOG, respectively, may also suggest that other HIF isoforms could  also 
possibly play a role in airway epithelial CD55 expression.  To date, no direct 
evidence is available for HIF-2α or HIF-3α mediated regulation of CD55.  
However, due to the ability of HIF-2α and HIF-3α to bind to HREs present on 
promoter regions of HIF-1α dependent genes, and the fact that these HREs 
comprise part of the promoter region for CD55, it is possible that the negative 
regulation of CD55 observed by HIF-1α may also incorporate regulation 
mediated by HIF-2α or HIF-3α.  As previously mentioned, a splice-variant of HIF-
3α is a dominant negative regulator of HIF-1α (175), (195).  Therefore, it is also 
possible that the HIF-1α mediated inverse regulation of CD55 may, in part, be 
driven by presence of splice variant for HIF-3α  (195).  Notably, while the 
isoforms of these hypoxia-inducible factors are structurally similar, they are not 
functionally identical  (135), (140).  Therefore, these HIF isoforms possess the 
ability to cooperatively work together.  Interestingly, these HIF isoforms still have 
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distinct mechanisms to regulate hypoxic responses in specific cell types (194).  
Expression of all three HIF isoforms may be temporally and differentially 
regulated depending on the specific cell type (135), (140).  Along with expression 
of HIF-1α, HIF-2α (174) and HIF-3α (175) have also been identified to be induced 
in lung epithelium under hypoxic stimuli.  Thus, while the possibility of other HIF-
1α isoforms has not been directly assessed in our experiments, their role in 
regulating CD55 on airway epithelium is certainly plausible.   
 
D.  Positive and Negative Transcriptional Regulation by HIF-1α 
Conventionally, the HIF-1α transcription factor is more commonly well-
known for its role as a transcriptional activator of genes.  However, in certain 
conditions, as indicated by our experimental studies, HIF-1α can also mediate 
transcriptional repression of genes.  As previously mentioned, regulation of HIF-
1α occurs at the post-translational level, whereby, the protein is stabilized and 
protected against proteosomal-degradation (134).  Notably, expression of HIF-1α 
may be observed in our normoxic conditions as seen in our normoxic controls 
due to its inducible nature.  Following its stabilization, HIF-1α translocates to the 
nucleus and binds to the constitutively expressed co-subunit, HIF-1β.  This 
heterodimeric complex can co-assemble either with co-activators or co-
repressors, and bind to HREs located within the promoter regions of the target 
gene to mediate its transcriptional activation or repression, respectively (134).  
While the specific mechanisms by which HIF-1α represses CD55 transcription 
still remains to be elucidated, HIF-1α mediated epigenetic modifications on DNA 
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sequence of CD55 may contribute to its transcriptional down-regulation.  Co-
activators and co-repressors possess functional characteristics for modulating 
epigenetic changes on the target genes.  While co-activators can initiate 
transcriptional activation of target genes via mechanisms such as histone 
acetylation (196), co-repressors can repress transcriptional activation by 
mechanisms such as deacetylation of histones and making them less accessible 
for transcription (197).  This histone deacetylase (HDAC) mediated co-repressor 
activity, may be one potential mechanism that is responsible for HIF-1α mediated 
transcriptional down-regulation of CD55.  Studies have indicated a role for 
several HDACs binding to HIF-1α including histone deacetylases 1, 2, 3, 4, 5, 7 
(HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7), and Sirtuin-3 (SIRT3) 
(198), (199), (200), (201).  However, the type of HDAC-HIF-1α complex formed 
varies depending on the cell type, the gene targeted for repression, and the 
extracellular or intracellular conditions in the context where repression of the 
target gene is necessary (202), (203).  On the contrary, certain HIF-1α and 
HDAC interactions can also result in transactivation of some genes (201), (204).  
Thus, deacetylation of histones may not be the only mechanism that potentially 
represses CD55 transcription.  Other functional characteristics of the co-
repressors, such as methylase or demethylase activity, may also be playing a 
role (205).    
Inverse regulation of CD55 by HIF-1α may also regulated by its 
competition with other transcription factors to bind to co-activators for 
transcriptional activation of genes such as CD55.  Due to the limited availability 
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of co-activators present in the nucleus, binding of these coactivators to HIF-1α 
may, in fact, result in less available coactivators to bind to transcription factors 
that could possibly induce CD55 transcription in hypoxic airway epithelium.  
Notably, it is also known that other transcription factors compete with HIF-1α to 
bind to co-activators for transcriptional activation (206), which may result in less 
binding of co-activators to HIF-1α.  Thus, providing a possible explanation for the 
observed induction of CD55 transcripts that surpass the normoxic basal 
transcripts seen in chetomin and siRNA in vitro studies.  Notably, the 3’ 
untranslated region of CD55 mRNA is comprised of AU-rich elements that can 
destabilize CD55 transcripts, unless the stabilizing protein HuR is bound to it 
(207).  Thus, it is possible that HIF-1α could prevent HuR binding to the AU-rich 
elements in CD55 mRNA which may result in decrease CD55 transcript levels 
(207).  Recent advances have also suggested that the orientation of the HREs 
present on the antisense strand of the target gene may also contribute to 
repression of genes mediated by HIF-1α (208), (209).  However, further studies 
will need to be conducted to determine the precise mechanism by which the HRE 
orientation may regulate HIF-1α dependent CD55 transcriptional down-regulation 
in airway epithelial cells.    
 
E.  Putative Mechanisms for HIF-1α Mediated Suppression of CD55  
 Our studies have reported transcriptional and post-translational down-
regulation of CD55 on airway epithelial cells, where HIF-1α expression is induced 
in the presence or absence of hypoxia.  However, a temporal lag is observed 
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between transcriptional and post-translational CD55 down-regulation.  While this 
interval between HIF-1α dependent suppression of CD55 mRNA and protein 
expression on airway epithelium, may result from amount of time it takes to go 
through the eukaryotic transcription-translation process (210), (211), which are 
temporally and spatially distinct, the differential regulation of CD55 transcripts or 
protein expression can also contribute to the observed lag period.  
Transcriptional repression of CD55 in airway epithelial cells can inhibit the 
translation of CD55 protein.  However, other HIF-1α dependent mechanisms 
must be present in order to down-regulate the existing membrane-bound CD55 
already present on the surface of these airway epithelial cells.    
Due to the presence of GPI-anchor on CD55, their down-regulation may 
be mediated by enzymatic cleavage through proteolytic proteins that are up-
regulated in hypoxic conditions such as PIPLC (212), or MMPs (77).  
Internalization of CD55 by oxidative stress can also result in its down-regulation.  
Notably, hypoxic conditions within the lung  can initiate oxidative stress by the 
production of reactive oxygen species (ROS) (213) or reactive nitrogen species 
(RNS) such as nitric oxide (NO) (214).  Thus, internalization of CD55 via 
oxidative stress may serve as another potential mechanism by which the CD55 
protein is down-regulated (215).  S-nitrosylation by NO can result in CD55 mRNA 
degradation by inhibiting HuR, a stabilizing protein, from binding AU-rich 
elements on the 3’ untranslated region of CD55 mRNA (207).  Other proteins 
reported to mediate down-regulation of membrane-bound CRPs, such as CD55, 
include IL-17A and activated complement proteins (76), (96).  In the context of 
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IPF and OB, airway epithelial expression of CD55, along with other membrane-
bound CRPs, were down-regulated by IL-17A or activated complement proteins 
(76), (96).  However up-regulation of IL-17A and complement activation has also 
been reported in lung IRI.  Particularly, since hypoxia is a component of ischemia 
(108), it is plausible that the cell surface down-regulation of CD55 seen in our 
experimental studies may be regulated by hypoxia induced IL-17A or 
complement activation (76).   
 
F.  Regulation of Complement Activity by Other CRPs in Airway Hypoxia 
Functionally characterized as a CRP, one major role for CD55 is to 
regulate complement activation.  Interestingly, local complement activation was 
observed in our in vivo hypoxic model at the same time-point as the down-
regulation of airway epithelial CD55 down-regulation was observed.  However, 
complement activation was not inhibited in hypoxic mice BALF where CD55 was 
restored due to HIF-1α silencing.  Thus, it is also possible that presence of serine 
proteases from other mechanisms initiated in the hypoxic environment, such as 
activation of the coagulation system, could maintain complement activation (216).  
It is also possible that complement activation can also be initiated by serine 
proteases present in leukocytes, such as neutrophils, that may be activated in 
hypoxia- induced inflammation.    
Stabilization of HIF-1α in normoxic mice by DMOG, does not result in 
complement activation despite the down-regulation of CD55.  Therefore, it is also 
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possible that presence of other CRPs; such as the mouse-specific CRRY; as well 
as, other membrane-bound or soluble CRPs may also play a role in modulating 
the activity of complement.  Thus, while hypoxia induced HIF-1α-dependent 
mechanisms down-regulate CD55, other CRPs may provide protection against 
complement-mediated in vivo injury in airway hypoxia by compensating for the 
loss of CD55.  Activation of complement within 24 hours post-hypoxia in our in 
vivo model, suggests that other hypoxia-driven mechanisms may attenuate the 
role for these other CRPs to control complement activity.  However, we have not 
directly investigated the role of other CRPs in our studies.  Contrary to our in vivo 
functional data, we did not assess complement activation in our in vitro studies, 
because although airway epithelial cells can synthesize complement proteins, in 
vitro hypoxic conditions, alone, will not induce complement activation since the 
presence of serine proteases are critical.    
 
G.  Therapeutic Relevance for Understanding HIF-1α Dependent CD55 
Regulation on Airway Epithelium 
To date, only limited studies have reported or identified mechanisms that 
regulate CD55.  However, to the best of our understanding, the current data is 
the first to identify the role of HIF-1α negatively regulating CD55 expression on 
airway epithelium.  Elucidating mechanisms that regulate expression of CD55 in 
the context of airway hypoxia, are of importance due to its role in several 
pulmonary pathologies such as OB, IPF, allergic asthma, and lung IRI (36) where 
hypoxia is a factor (117), (118), (121), (125).  In these lung diseases where 
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hypoxia is known to occur, complement activation is also observed (76), (96).  
Notably, in OB and IPF down-regulation of CD55 and other membrane-bound 
CRPs correlate with the local complement activation which may contribute to the 
pathogenesis of these diseases (76), (96).  Therefore, understanding how to 
regulate the expression of CRPs, such as CD55, may help attenuate some of the 
complement-mediated lung injuries associated with some of the hypoxia and 
complement mediated pulmonary diseases like OB or IPF.    
Our studies provide insight into potential therapeutic interventions for 
preserving CD55 expression in pulmonary pathologies where down-regulation of 
CD55 and local complement activation are observed.  Through our experimental 
studies, we have shown that airway hypoxia induced HIF-1α mediates CD55 
down-regulation on airway epithelium.  Thus, one possible mechanism to 
preserve CD55 expression in pulmonary diseases; such as asthma, OB, IPF, or 
lung IRI; where hypoxia occurs, is to inhibit the expression of HIF-1α.  However, 
the caveat to this is that HIF-1α plays a major role in other biological processes, 
such as angiogenesis and metabolism, that help adapt cells and tissues to these 
hypoxic conditions at the cellular and physiological level (135).  Therefore, while 
inhibiting HIF-1α expression may preserve CD55 expression and protect against 
complement activation, it may also ultimately result in cell death due to the lack 
of the cells’ ability to adapt to hypoxia by mediating physiological responses that 
are critical for survival.  On the contrary, HIF-1α does not always promote 
survival in hypoxic conditions.  Depending on the severity of hypoxia, HIF-1α can 
also induce cell apoptosis.  Therefore, due to the various cellular effects that HIF-
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1α has in hypoxia, other options may be more suitable for potential therapeutic 
interventions that could regulate complement activity in hypoxic pulmonary 
pathologies.   
Over-expression of CD55 may be the more appropriate therapeutic option 
in these pulmonary diseases where local CD55 down-regulation and complement 
activation are observed.  To protect and attenuate some of the complement-
mediated inflammation observed in lungs of asthmatic individuals, CD55 protein 
containing SCRs could be directly delivered into the lungs in the form of 
aerosolized proteins via inhalers or nebulizers as seen in other treatments used 
for asthma (217), (218).  In terms of IPF, several pharmacological treatments are 
utilized to prevent or manage IPF.  However, the efficacy of the drugs were 
variable, and none of them specifically targeted complement activation.  
Therefore, the only successful and promising treatment known to prolong survival 
in individuals with IPF is lung transplantation (219).  Interestingly, however, even 
during or after lung transplantation, injury of the lungs are observed in the form of 
lung IRI or OB, respectively.  Notably, it is possible that complement-mediated 
injury seen in lung IRI may predispose the lung into developing OB.  Therefore it 
is important to target complement activation during the transplant procedure to 
mitigate complement-mediated lung damage, and improve the outcome of lung 
transplant survival.   
As previously mentioned, while several inflammatory mechanisms play a 
role in the onset of OB and lung IRI, complement activation is a common factor in 
both.  More so, down-regulation of CRPs, such as CD55, is also observed in OB.  
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Thus, over-expressing CD55 during the transplant procedure via ex vivo lung 
perfusion (EVLP), may attenuate some of the complement-mediated injury seen 
in lung IRI or OB.  EVLP is a technique that involves improving the state and 
condition of the donor lungs prior to transplant by flushing them with acellular 
normo-thermic perfusate (220), thereby, controlling complement-dependent 
injuries associated with lung IRI or OB by over-expressing CD55 during the 
EVLP procedure.  This can be achieved by flushing the lungs during EVLP with 
soluble CD55.  This enables the soluble CD55 to inhibit local complement 
activation by preventing or dissociating C3 and C5 convertases in the lung.  
Following lung transplant, alloimmune-mediated mechanisms may also initiate 
local and systemic complement activation in OB.  Over-expression of CD55 as a 
therapeutic intervention in these conditions may involve using aerosolized CD55 
delivery as indicated for asthmatic patients for local complement activation, or the 
possibility of injecting soluble CD55 intravenously in transplant recipients to 
regulate systemic complement levels.    
Despite the innovative concept of CD55 over-expression as a therapeutic 
treatment for several hypoxia-mediated pulmonary diseases where activation of 
complement and CD55 down-regulation are observed, the exogenous over-
expression of CD55 may not result in complete abrogation of the lung injury.  
This is due to the fact that many other inflammatory mechanisms, besides 
complement activation, also regulate the pathogenesis of OB, IPF, asthma, and 
lung IRI.  While down-regulation of the CRP, CD55, can correlate with the 
increased complement activation observed in the lung diseases, presence of 
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other membrane-bound or soluble CRPs also regulate complement activity.  
Therefore, the most promising therapeutic intervention would be one that targets 
not only the complement activation via over-expression of CRPs, such as CD55, 
but one that also focuses on targeting other inflammatory mechanisms like 
blocking of adhesion molecules.  Interfering with the adhesion molecules on the 
endothelium can disrupt the recruitment of inflammatory leukocytes like 
neutrophils to the site of injury that contribute to exacerbated inflammation.   
Thus, targeting multiple factors that cause lung injury may serve to attenuate or 
lessen the injury/inflammation.  Although, our studies of HIF-1α mediated CD55 
down-regulation in hypoxic airways do not provide direct therapeutic relevance in 
the clinical setting, we did highlight a new mechanism by which airway epithelial 
down-regulation of CD55 occurs.  Consequently, the therapeutic relevance of our 
experimental studies lies in understanding the mechanisms to preserve CD55 
expression or over-express them in the lungs to attenuate complement-mediated 
pulmonary injuries.    
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                                V.  CONCLUSIONS 
 CD55, a membrane-bound CRP, is constitutively expressed on the 
surface of many cell types including airway epithelium (69), (76).  However, 
airway epithelial down-regulation of CD55 observed in several pulmonary 
diseases associated with hypoxia, led us to hypothesize that hypoxic conditions 
may be responsible for suppression of CD55.  In particular, hypoxia-induced 
transcription factor, HIF-1α, may be regulating the expression of CD55.  Notably, 
by assessing expression of other membrane-bound CRPs such as CD46 or 
CRRY in our in vitro and in vivo studies, we recognized the hypoxia mediated 
protein down-regulation of membrane- bound CRP is specific to CD55 not CD46 
or CRRY (Figures 23, 24, 25).  In our studies we further demonstrated the role 
for HIF-1α in mediating CD55 down-regulation in airway epithelial cells.  
Exposing SAECs or our mouse model to hypoxic conditions, resulted in down-
regulation of CD55 in airway epithelium (Figures 22, 24).  Interestingly this effect 
was only seen in C57BL/10 mice and not C57BL/6 mice, which may give rise to 
the possibility that various strains of mice may possess differential expression of 
CRPs like CD55 (Figure 26).  Thus, to verify the presence of hypoxia, we 
reported the expression of a potent hypoxia-induced protein, HIF-1α in vitro 
(Figure 20).  However, assessing HIF-1α expression in our hypoxic mice model 
was difficult due to its short half-life.  Therefore, we further confirmed the 
presence of hypoxia in vitro and in vivo, by assessing transcriptional expression 
of CA9, an indicator of HIF-1α transcriptional activity (Figures 20C, 21).  To verify 
that the hypoxia-induced HIF-1α, was responsible for suppression of in vitro and 
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in vivo airway epithelial CD55, we inhibited expression of HIF-1α using chetomin 
(Figures 28, 30) or HIF-1α siRNA (Figures 31, 34).  Notably, HIF-1α inhibition via 
chetomin (Figures 28, 30) or HIF-1α siRNA (Figure 33, 35), resulted in recovery 
of CD55 expression on airway epithelial cells in our in vitro and in vivo studies.  
Inhibition of HIF-1α was further confirmed by data depicting that CA9 transcripts 
were down-regulated in hypoxic SAECs or hypoxic mice lungs where HIF-1α was 
inhibited by chetomin (Figures 29, 30D) or silenced by siRNA (Figures 32, 35).  
Furthermore, we verified that hypoxia-mediated CD55 down-regulation that was 
occurring, was dependent on HIF-1α rather than other hypoxia-driven 
mechanisms.  This was achieved by stabilizing HIF-1α expression in normoxic in 
vitro and in vivo conditions via DMOG treatment (Figures 38, 41) or by 
transducing normoxic SAECs with adenoviral vector that expresses constitutively 
activated HIF-1α (Figure 45).  Even in the absence of hypoxia, in vitro or in vivo 
stabilization of HIF-1α resulted in CD55 down-regulation (Figures 40, 43, 47).  
Increased transcript levels of CA9 was observed in normoxic SAECs (Figures 39, 
46) or mice lungs (Figure 42) where HIF-1α was stabilized.  Thus, confirming the 
induction of HIF-1α in these normoxic conditions.  Interestingly, down-regulation 
of CD55 expression in our hypoxic in vivo models within 24 hours, correlated with 
complement activation observed in BALF of these 24 hour hypoxic mice.   
 These results support our hypothesis that HIF-1α regulates expression of 
CD55 on airway epithelial cells.  From these data, we can hypothesize potential 
mechanisms by which HIF-1α represses CD55 mRNA.  One possible mechanism 
is that HDACs enable HIF-1α-coactivator complex to bind to rHRE regions on 
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genes like CD55 where HIF-1α acts to repress their mRNA (Figure 48).  
Therefore, in hypoxia where HDAC, HIF-1α, or HIF-1α- coactivators are inhibited 
via trichostatin A, chetomin, or HIF-1α siRNA respectively, then we see that 
CD55 mRNA is restored to basal levels (Figure 49).  HIF-1α is also known to 
induce expression of proteolytic enzymes like MMPs (221).  Thus, while it is 
possible that CD55 mRNA repression which occurs by HIF-1α transcription as 
suggested by our data,  prevents translation of further CD55 protein, the down-
regulation of the already present GPI-anchored CD55 protein on airway epithelial 
cell surface in hypoxia may occur by other HIF-1α  dependent mechanisms.  One 
such mechanism may involve MMPs that could cleave CD55 protein from cell 
surface, hence, why we see CD55 down-regulation.  It is possible that HIF-1α 
induces transcription of MMPs which then go on to be translated and mediate 
proteolytic cleavage of CD55 from cell surface.  This could provide the possible 
explanation as to why there is a temporal difference between down-regulation of 
CD55 mRNA and CD55 protein in our in vitro studies.   
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Figure 48.  Proposed Mechanistic Model.  In normoxic conditions, PHDs are 
activated and hydroxylate HIF-1α which targets it for proteosomal degradation.  
However, in hypoxic conditions, PHDs are not activated and HIF-1α protein is 
stabilized.  In normoxic conditions, HIF-1α protein can also be stabilized by 
DMOG or AdCA5.  Stabilization of HIF-1α enables it to bind to its constitutively 
expressed partner, HIF-1β, and the complex is translocated to the nucleus.  
Once in the nucleus, HIF-1α can complex with coactivators like CBP/p300, and 
bind to HRE regions on promoter region of genes.  One proposed hypothesis is 
that down-regulation of CD55 mRNA may occur when HDACs bind this HIF-1α-
coactivator complex which may enable it to bind to rHRE on gene of interest.  
However, inhibiting HIF-1α by siRNA or chetomin or inhibiting HDACs can 
reverse this phenomenon.  HIF-1α can also induce expression of proteins like 
MMPs which may contribute to protein down-regulation of CD55.    
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      VI.  FUTURE STUDIES 
 While our findings are novel in that we have identified HIF-1α mediated 
negative regulation of CD55 on airway epithelial cells, some limitations that still 
exist within our studies result in unresolved questions that may be elucidated by 
future studies.  Previous studies have reported a correlation between the 
presence of HIF-1α and induction of CD55.  This was confirmed by studies 
demonstrating the direct binding of HIF-1α to HREs present on CD55 (80).  Due 
to the negative regulation of CD55 by HIF-1α in our studies, we are limited in that 
we have not assessed direct binding of HIF-1α to the CD55 promoter region by a 
chromatin immunoprecipitation (CHIP) assay.  However, by performing a CHIP 
assay using anti-HIF-1α and an antibody against a specific HDAC, we may be 
able to detect what co-activators or co-repressors complexes are present during 
the HIF-1α and CD55 interaction.  This may gave insight into how HIF-1α 
negatively regulates CD55 (80).   
  Future studies will also need to be conducted to elucidate the precise 
mechanism by which HIF-1α negatively regulates CD55 expression in our model.  
It has been widely reported that HIF-1α can bind to co-repressors such as 
HDACs to inhibit gene expression (222).  Preliminary studies suggest a role for 
HDACs in regulating airway epithelial CD55 expression under hypoxic conditions 
(Figure 49).  SAECs exposed to 6 hours of hypoxia restored CD55 mRNA 
expression when treated with optimal dose of HDAC inhibitor trichostatin A 
(Figure 49, p<0.05, p<0.001).    
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Figure 49.  Inhibiting HDACs By Trichostatin A Restores CD55 Expression In 
Hypoxic SAECs.  Hypoxic SAECs treated with trichostatin A results in recovery of 
CD55 mRNA.  Data represents mean+SEM, n=3; ***p<0.001 vs 6h hypoxia, 
*p<0.05 vs 6h hypoxia; One-Way ANOVA with Bonferroni post-test.    
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 One future study that could provide insight into how the HIF-1α mediated 
negative regulation of CD55 occurs on airway epithelial cells, is to screen for the 
presence of various HDACs in our in vivo and in vitro hypoxic versus normoxic 
studies.  Based on these results, a CHIP assay could be utilized to confirm the 
recruitment of HIF-1α and the specific HDAC to the HRE in CD55 promoter 
region (199).  From these studies, the role of the particular HDAC identified in 
HIF-1α mediated negative CD55 regulation, can be further assessed by 
examining CD55 expression when this HDAC is silenced.  It has also been 
reported that HIF-1α mediated repression of certain genes may be regulated by  
orientation of HREs in the anti-sense strand (208), (209), (223).  This could be 
assessed by performing a promoter analysis using a database search for CD55 
(199), which may show if one if the sites has an inverted or reverse sequence for 
HRE.  Furthermore, since CD55 has at least three HRE sites (80), a series of 
deletion mutants can be constructed on CD55 promoter to assess which HRE is 
the site responsible for the transcriptional role of HIF-1α on HREs present within 
CD55 promoter (199).    
 Another area of this study that requires further investigation is identifying 
the mechanisms that lead to CD55 protein down-regulation in these hypoxic 
airway epithelial cells.  While HIF-1α mediated CD55 transcript down-regulation 
may prevent translation of more CD55 protein expression, the down-regulation of 
the pre-existing CD55 expression present on the cell surface may result from 
cleavage of the GPI anchor by proteolytic enzymes.  There are several 
proteolytic enzymes that may contribute to CD55 down-regulation.  However, it 
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has been reported that hypoxia, in particular, HIF-1α can induce expression of 
proteolytic enzymes known as matrix metalloproteinases (MMPs) (134).  The role 
of such enzymes in regulating CD55 protein expression in hypoxic conditions, 
could be determined by inhibiting MMP activity and assessing if CD55 expression 
is preserved.  To assess which particular MMP may be responsible for CD55 
down-regulation, a multiplex MMP ELISA array may be used (224).   
 Although our studies showed a promising role for HIF-1α for airway 
epithelial CD55 regulation, further studies need to be conducted to elucidate how 
intervention in this mechanism could attenuate complement-mediated 
inflammation observed in hypoxia-associated pulmonary diseases.  While 
complement activation has been observed in asthma and lung IRI, another 
potential study would be to assess CD55 expression on airway epithelium of 
these particular hypoxic pulmonary diseases, because that has not been directly 
assessed.  A caveat to these and other hypoxic pulmonary diseases like OB and 
IPF, is that other mechanisms besides hypoxia could be suppressing CD55.  
Regardless of the mechanisms involved in airway epithelial CD55 down-
regulation in these lung conditions, it would still be interesting to analyze if down-
regulation of CD55 contributes to local complement activation.  If the latter 
scenario is true, then the over-expression or preservation of CD55 could be 
utilized in such pulmonary diseases to control or inhibit complement activation.  It 
has been reported that local complement activation, and CD55 down-regulation 
occurs in the transplanted lung with OB (76).  Whereas, blocking complement 
activation attenuates incidence of OB (76).  Therefore, it would be beneficial to 
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intervene in the mechanism that mediates HIF-1α-dependent CD55 down-
regulation to protect the lung from complement mediated injury.  This could be 
assessed by using the mouse OB model.  Prior to the transplant, HIF-1α 
expression could be locally silenced in the mouse lung via intratracheal 
instillation of HIF-1α siRNA or chetomin.  In theory, HIF-1α silencing would 
mitigate its induction in hypoxic conditions such as IRI that occur during lung 
transplant.  Thus, expression of CD55 would be preserved on the airway 
epithelium of the transplanted lung.  However, as previously mentioned, one 
stipulation with this study is that silencing of HIF-1α would also inhibit its 
expression for other processes such as metabolism or pH regulation which aid in 
adapting the cells or the tissues to hypoxic conditions (225).  Therefore, the more 
appropriate method may be to locally over-express soluble CD55 containing 
regions critical for complement regulation in the donor mouse prior to lung 
transplant.  In this manner, even if induction of HIF-1α occurs, and CD55 is 
down-regulated on airway epithelium, the exogenous presence of soluble CD55 
can help protect the transplanted lung from complement injury.  Additionally, we 
also retain the HIF-1α expression for processes critical for hypoxic adaptions.  
Over-expression of CD55 in the donor lung during the transplant procedure can 
be of clinical relevance as well.  As previously mentioned, the therapeutic 
relevance of overexpression of CD55 during the transplant procedure can be 
achieved with the goal of improving the quality of the donor lungs making them 
more suitable for transplant.  This can be mediated by the use of soluble CD55 in 
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perfusing the lungs during EVLP to attenuate complement activation that may 
occur during the hypoxic phase in lung IRI.    
 Detrimental effects of hypoxia are not limited to airway epithelium.  Due to 
the ubiquitous nature of CD55 expression, further studies can also be conducted 
to assess how hypoxia-induced HIF-1α affects CD55 expression on other cell 
types present within the lungs such as lymphocytes and other leukocytes.  This 
may shed light on other pathways that can activate complement in hypoxic lungs.   
While CD55 is known to regulate complement activation, recent findings have 
suggested its role in binding to CD97 (226).  This may be beneficial in the sense 
that CD55 can also initiate other aspects of the immune system even if it keeps 
complement activation in check.  It has also been reported that expression of 
CD55 on mucosal epithelial, can bind to CD97 on cells such as neutrophils and 
mediate its epithelial transmigration resulting in further inflammation (80), (227).  
Notably, CD55 also plays a role in adaptive immunity by being involved in CD4+ 
T cell co-stimulation and activation (228).  Therefore, it would be interesting to 
investigate the effects of HIF-1α mediated CD55 down-regulation on other innate 
or adaptive cell types present within the lung.   
   Since the primary focus of our studies involved HIF-1α mediated effects 
on CD55 expression within airway epithelium, it would also be useful to assess 
the effects of HIF-1α of other membrane-bound CRPs such as CRRY and CD59 
on airway epithelium or on local soluble CRPs present in the interstitium of the 
lung.  Notably, understanding how HIF-1α impacts airway epithelium or 
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leukocytes expressing the complement receptors, C3aR and C5aR, can also be 
further investigated.    
 Another limitation present within our studies was the amount of oxygen 
concentration we utilized to mimic hypoxia.  While most of our in vitro and in vivo 
hypoxic studies were performed in 1% O2 or 10% O2, respectively, it would be 
interesting to assess what oxygen concentration induces HIF-1α, and how this 
affects CD55 expression under varying oxygen levels.  This can be pursued by 
repeating all of the indicated hypoxic SAEC and animal experiments under 
varying oxygen concentrations.  However, one caveat of assessing varying 
oxygen levels in vivo is that exposing mice to severe hypoxia (less than 10% O2) 
for long time points may be prove to be lethal (184), (185).  However, short-term 
exposure of mice to less than 10% O2 may not be harmful.  Similarly, future 
studies could also assess in vitro and in vivo HIF-1α and CD55 expression in 
hypoxic conditions over varying time-points, other than the 6 and 24 hours that 
we utilized in our studies.   
 Another aspect of this study that entails further investigation is the 
analysis of other HIF isoforms in regulating CD55 expression on airway 
epithelium.  As previously mentioned, HIF-2α and HIF-3α can also be induced in 
hypoxic airway epithelial cells (174), (175).  Notably, while we have utilized 
specific mechanisms to specifically intervene with HIF-1α such as HIF-1α siRNA 
or AdCA5, treatments with DMOG and chetomin can also target other HIF- 
isoforms (151), (186).  Thus, it is possible that HIF-2α or HIF-3α can also play a 
role in regulating CD55 expression on airway epithelial cells.  To specifically 
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investigate the role of these HIF isoforms in CD55 regulation, HIF-2α or HIF-3α 
siRNA can be transfected in hypoxic SAECs or be intratracheally instilled in mice 
prior to their hypoxic exposure and CD55 expression can be assessed.    
 Completion of these future studies will highlight the importance of the 
amount of oxygen concentration, as well as, the time-frame required for 
regulation of CD55 in hypoxic airway epithelium.  Similarly, these suggested 
experiments may also indicate a role for other HIF isoforms or CRPs in regulating 
complement activation in hypoxia- associated pulmonary diseases.  Collectively, 
these potential studies will provide new insight on our current research on how 
CD55 can be regulated in hypoxic airway epithelium.    
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